Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# Touch Medical Media Limited

## Sitemaps
- [XML Sitemap](https://touchoncology.com/sitemap_index.xml): Includes all crawlable and indexable pages.

## Journal Articles
- [Choosing the appropriate adjuvant therapy in patients with melanoma undergoing neoadjuvant treatment](https://touchoncology.com/dermatologic-cancers/journal-articles/choosing-the-appropriate-adjuvant-therapy-in-patients-with-melanoma-undergoing-neoadjuvant-treatment/): In parallel, emerging biomarkers may further refine postoperative decision-making. Correlative analyses from pivotal neoadjuvant trials have provided important biological insights, with Huang et al. demonstrating expansion of tumor-resident T-cell clones following PD-1 blockade, and OpACIN/OpACIN-neo identifying interferon (IFN)-γ-associated gene expression signatures and tumor mutational burden (TMB) as correlates of pathologic response and relapse-free survival, with the combination of high IFN-γ signature and high TMB associated with a 100% pathologic response rate.20,21 Biomarker data from more recent trials remain comparatively limited: correlative studies in SWOG S1801 were announced alongside the primary results but have not yet been reported in mature form, while NADINA’s first biomarker analysis presented alongside its 2-year update similarly identified TMB, PD-L1 expression and IFN-γ signature as associated with improved EFS, with combined high-biomarker subgroups reaching close to 100% EFS at 24 months. These findings are broadly consistent with the OpACIN/OpACIN-neo data but still require longer follow-up and prospective validation before they can inform clinical decision-making. Taken together, increasing evidence supports IFN-γ-associated immune activity as a broader predictor of response and outcome in melanoma immunotherapy.22,23
- [Where are we now: Clinical utility and challenges of circulating tumor DNA in breast cancer](https://touchoncology.com/breast-cancer/journal-articles/where-are-we-now-clinical-utility-and-challenges-of-circulating-tumor-dna-in-breast-cancer/): Circulating tumor DNA (ctDNA) has emerged as an innovative and minimally invasive tool in precision oncology. With a short half-life of 30–120 min, ctDNA provides real-time insight into tumor dynamics.1 In early-stage breast cancer, there is growing evidence supporting its potential for minimal residual disease (MRD) detection and recurrence monitoring. In metastatic breast cancer (MBC), ctDNA has become an established biomarker for identifying genomic alterations and detecting resistance mechanisms.
- [Foreword – touchREVIEWS in Oncology & Haematology, Volume 22, Issue 1, 2026](https://touchoncology.com/dermatologic-cancers/journal-articles/foreword-touchreviews-in-oncology-haematology-volume-22-issue-1-2026/): This issue of touchREVIEWS in Oncology & Haematology brings together a diverse collection of articles reflecting the growing complexity of cancer care and the continued evolution of precision medicine across tumour types. From rare malignancies and treatment-related challenges to emerging targeted therapies and novel biological insights, the contributions highlight both recent progress and the significant unmet needs that remain across oncology.
- [Targeting HER2 in advanced non-small cell lung cancer: The emerging role of zongertinib](https://touchoncology.com/lung-cancer/journal-articles/targeting-her2-in-advanced-non-small-cell-lung-cancer-the-emerging-role-of-zongertinib/): HER2 gene amplification in NSCLC refers to an increased number of ERBB2 gene copies within tumor cells. Amplification can occur through two distinct mechanisms: as a primary oncogenic driver, particularly in adenocarcinomas of patients with a smoking history, or as an acquired resistance mechanism following targeted therapies such as EGFR TKIs.28–30 High-level HER2 amplification has been associated with poor clinical outcomes, including shorter disease-free survival and a greater likelihood of pleural invasion.31 While HER2 amplification can lead to overexpression of the HER2 protein, it has not consistently predicted response to HER2-targeted therapies, and the clinical benefit from agents like trastuzumab has been limited in this setting.32 However, antibody–drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) have shown preliminary activity in select amplified tumors, particularly those with high-level amplification.28
- [Imipridones in Diffuse Midline Gliomas: A Review of the Timeline from Drug Discovery to Dopamine Receptor D2 and Caseinolytic Protease P (ClpP) Target Identification and the Trials Leading to FDA Approval](https://touchoncology.com/neuro-oncology/journal-articles/imipridones-in-diffuse-midline-gliomas-a-review-of-the-timeline-from-drug-discovery-to-dopamine-receptor-d2-and-caseinolytic-protease-p-clpp-target-identification-and-the-trials-leading-to-fda-appr/): Dopamine is a catecholamine neurotransmitter whose function ranges from voluntary movement to reward behaviour and other neurological functions.17 Dopamine-related signalling occurs through two groups of G-protein-coupled receptors: the D1-like receptors, comprised of dopamine receptor D1 and dopamine receptor D5 (DRD5), which activate adenylyl cyclase, and the D2-like receptors, comprised of dopamine receptor D2 (DRD2), dopamine receptor D3 and dopamine receptor D4, which inhibit adenylyl cyclase. Though beyond the scope of this review, a link between dopamine and cancer has been posited for decades, stemming from observations of an inverse linkage between Parkinson’s disease (a dopamine-deficiency disorder) and cancer, as well as complex and conflicting relationships between cancer and the use of dopaminergic antipsychotics.18 This was further clarified in the molecular era when reviews of The Cancer Genome Atlas (TCGA) revealed broad DRD2 overexpression across a variety of tumour types, including the aggressive brain tumor glioblastoma (GBM), that correlated with poor prognosis.19
- [Skin Cancers and Acquired Immunosuppression: Epidemiology and Emerging Management Strategies](https://touchoncology.com/dermatologic-cancers/journal-articles/skin-cancers-and-acquired-immunosuppression-epidemiology-and-emerging-management-strategies/): An immunosuppressed person is one whose immune function is impaired by underlying disease and/or immunosuppressive medications, resulting in reduced immunosurveillance against malignant cells and increased vulnerability to opportunistic infections. Longstanding immunosuppression has been linked to increased risk for cutaneous (among other) malignancies for over half a century.1 Intrinsic patient characteristics, including advanced age, lighter skin phototype and personal and family history, shape baseline risk for many skin cancers.2,3 In addition to these factors, the main environmental risk factor for cutaneous malignancies, ultraviolet (UV) radiation exposure, causes immunosuppression in the skin, leading to a tumourigenic environment.4 Other conditions associated with skin cancers, such as xeroderma pigmentosum and Li–Fraumeni syndrome, can lead to markedly augmented risk over an individual’s lifespan.5
- [Bridging the Evidence Gap in Small Bowel Adenocarcinoma: Current Standards, Biomarker-selected Therapies and Novel Antibody–Drug Conjugate-based Clinical Initiatives](https://touchoncology.com/gastrointestinal-cancers/journal-articles/bridging-the-evidence-gap-in-small-bowel-adenocarcinoma-current-standards-biomarker-selected-therapies-and-novel-antibody-drug-conjugate-based-clinical-initiatives/): Against this backdrop, antibody–drug conjugates (ADCs) have emerged as a promising modality that may expand therapeutic options beyond genomics-defined subsets. Recent translational studies have begun to define the ADC-relevant surface antigen expression in SBA and have informed the launch of investigator-initiated trials.15 This article summarizes the clinicopathological and molecular landscape of SBA, current systemic treatment approaches and their limitations, tumour-agnostic options in molecularly selected subgroups, emerging ADC targets supported by translational evidence and the evolving clinical trial landscape, with the aim of identifying near-term priorities to improve outcomes in this rare disease.
- [What are the Latest Advances in Pancreatic Cancer Care?](https://touchoncology.com/pancreatic-cancer/journal-articles/what-are-the-latest-advances-in-pancreatic-cancer-care/): The integration of artificial intelligence (AI) into clinical practice is transforming PC management, with advancements in diagnosis, biomarker detection, treatment and prognosis (Figure 3).134
- [The Impact of Corticosteroid Use on the Efficacy and Safety of Checkpoint Inhibitors Across Cancer Types](https://touchoncology.com/immunotherapy/journal-articles/the-impact-of-corticosteroid-use-on-the-efficacy-and-safety-of-checkpoint-inhibitors-across-cancer-types/): Immune checkpoint inhibitors (ICIs) act by blocking inhibitory pathways such as programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), thereby restoring T-cell activity and promoting tumour cell destruction.1,2 The ability of tumours to evade the immune system is a significant drawback of conventional treatments that immunotherapy has addressed in a revolutionary way. These treatments interfere with the molecular ‘shields’ that cancer cells use to stifle immune activity by targeting immune checkpoints like CTLA-4, PD-1 and PD-L1. Through natural immune surveillance, this reactivates T cells and restores the body’s ability to recognize and eliminate cancerous cells.1,2
- [Modulating Cancer Immunotherapy Through the Intestinal Microbiota: Mechanisms, Clinical Evidence and the Emerging Role of Faecal Microbiota Transplantation](https://touchoncology.com/gastrointestinal-cancers/journal-articles/modulating-cancer-immunotherapy-through-the-intestinal-microbiota-mechanisms-clinical-evidence-and-the-emerging-role-of-faecal-microbiota-transplantation/): The intestinal microbiota, composed of approximately 1,000 species and over 100 trillion micro-organisms, plays a vital role in host physiology, including metabolism, barrier function and immune regulation.1 Disruption of this delicate host–microbiota balance – known as dysbiosis – has been implicated in the development of inflammatory bowel disease, metabolic disorders and various cancers. In recent years, the influence of the intestinal microbiota on the immune system has drawn increasing attention, particularly in the context of cancer immunotherapy.
- [Foreword – touchREVIEWS in Oncology & Haematology, Volume 21, Issue 2, 2025](https://touchoncology.com/gastrointestinal-cancers/journal-articles/foreword-touchreviews-in-oncology-haematology-volume-21-issue-2-2025/): It is with great pleasure that we present the latest edition of touchREVIEWS in Oncology & Haematology. This edition showcases the continued advances and innovation reshaping cancer care, as well as highlighting the continued unmet needs and challenges associated with more difficult-to-treat cancers.
- [New Adjuvant Treatment Modalities in Thrombotic Thrombocytopenic Purpura: A Review of Recent Clinical Trials](https://touchoncology.com/hematology/journal-articles/new-adjuvant-treatment-modalities-in-thrombotic-thrombocytopenic-purpura-a-review-of-recent-clinical-trials/): TTP is now recognized to consist of a classical acquired form, mediated by an autoantibody against ADAMTS13 (immune thrombotic thrombocytopenic purpura ), and a congenital deficiency of ADAMTS13 (congenital thrombotic thrombocytopenic purpura ), also known as Upshaw–Shulman syndrome. Treatment with plasma exchange (PEX) is now known to (1) replace ADAMTS13 protein and (2) remove circulating autoantibodies, with striking reduction in mortality rate to approximately 20%.3 However, relapses occur in 41–74% of patients.4,5 Given that 16% of cases are refractory to primary treatment with PEX and corticosteroids, ongoing efforts continue to identify and characterize new medications that may improve remission rates, prevent relapses and improve long-term outcomes.3
- [Think Horses, But Do Not Forget the Zebras: Early-onset Lung Cancer](https://touchoncology.com/lung-cancer/journal-articles/think-horses-but-do-not-forget-the-zebras-early-onset-lung-cancer/): Immunotherapy, alone or combined with chemotherapy, plays a role in treating metastatic patients without actionable mutations. Although young adults tend to have a lower tumour mutation burden and are more often non-smokers, which may correlate with less responsiveness to immune checkpoint inhibitors (ICIs), some benefits have been observed.81 Given the relatively low PD-L1 expression in many of these tumours and decreased expression of immune-related genes in the tumour microenvironment, the choice of immunotherapy must be individualized.57 A large dataset including 53,719 patients showed that the 2-year survival benefit from ICIs was more pronounced in patients aged 55 years and younger compared with those aged 75 years and older. Notably, ICI-chemotherapy combinations were more frequently administered to younger patients.82 However, in a real-world analysis of patients under 40 years, ICIs were not an independent predictor of improved survival.83
- [Frontline Therapy in Advanced Hepatocellular Carcinoma](https://touchoncology.com/gastrointestinal-cancers/journal-articles/frontline-therapy-in-advanced-hepatocellular-carcinoma/): Emerging evidence suggests that specific subgroups of patients with advanced HCC may derive greater benefit from immunotherapy or targeted therapies based on aetiology, tumour biology and biomarkers.5
- [Latest in Cervical Cancer Management](https://touchoncology.com/gynecologic-cancers/journal-articles/latest-in-cervical-cancer-management/): Cervical cancer (CC) is the fourth most common cancer among women worldwide, with an estimated 604,000 new cases and 342,000 CC-related deaths in 2020.1#
- [Foreword – touchREVIEWS in Oncology & Haematology, Volume 21, Issue 1, 2025](https://touchoncology.com/dermatologic-cancers/journal-articles/foreword-touchreviews-in-oncology-haematology-volume-21-issue-1-2025/): We begin with an editorial by Isabela Wen-Chi Chang et al. examining the ROSEWOOD trial (ClinicalTrials.gov identifier: NCT03332017). Their discussion on zanubrutinib combined with obinutuzumab highlights a potential advancement in the management of relapsed/refractory follicular lymphoma, suggesting the value of next-generation BTK inhibition.
- [Antibody–drug Conjugates in Head and Neck Cancer: Current and Future Perspectives](https://touchoncology.com/head-and-neck-cancer/journal-articles/antibody-drug-conjugates-in-head-and-neck-cancer-current-and-future-perspectives/): Antibody–drug conjugates (ADCs), previously known as immunoconjugates, represent an emerging class of treatment contributing to the field of oncology. The first ADC approved by the US Food and Drug Administration (FDA) in 2000 was the CD33-targeting agent gemtuzumab ozogomycin.13,14 In the following years, the introduction of ADCs has been extensive in haematological malignancies, including acute myelogenous leukeamia, multiple myeloma and diffuse large B-cell lymphoma. Ado-trastuzumab emtansine (T-DM1) was the first FDA-approved ADC for solid malignancy (breast cancer) in 2013, and five other ADCs have since received FDA approval across multiple indications for solid malignancies, including breast, cervical, ovarian and urogenital cancer.15 Potential targets are currently being investigated to determine the role of ADCs in treating HNCs, particularly in the relapsed refractory metastatic setting.
- [Central Nervous System as a Sanctuary for Advanced Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer](https://touchoncology.com/lung-cancer/journal-articles/central-nervous-system-as-a-sanctuary-for-advanced-epidermal-growth-factor-receptor-mutant-non-small-cell-lung-cancer/): The objective of this review is to describe the central nervous system (CNS) as a sanctuary for advanced EGFR-mutant NSCLC and to discuss the therapeutic options available for these patients, focusing on drugs such as osimertinib and amivantamab, which have shown promising results in treating brain metastasis.
- [Current and Future Applications of Liquid Biopsy in Melanoma](https://touchoncology.com/dermatologic-cancers/journal-articles/current-and-future-applications-of-liquid-biopsy-in-melanoma/): In solid tumours, only a few LB-based methods have been validated and incorporated into clinical practice. However, unsolved challenges result from the complexity of personalizing biomarkers for solid tumours, as they are continuously affected by genetic and environmental factors, which complicates clinical interpretation. Well-established examples of LB use in solid tumours include lung and colorectal cancers, where ctDNA-based diagnostic markers have already been approved by the US Food and Drug Administration, and the CELLSEARCH® CTC test (Menarini Silicon Biosystems, a subsidiary of the Menarini Group, Florence, Italy), which is used as a diagnostic tool for metastatic colon, breast and prostate cancers.12
- [Emerging Cell Therapy Approaches in Relapsed/Refractory Acute Myeloid Leukaemia in Older Adults](https://touchoncology.com/hematology/journal-articles/emerging-cell-therapy-approaches-in-relapsed-refractory-acute-myeloid-leukaemia-in-older-adults/): Patients diagnosed with AML are risk stratified for survival outcomes on numerous factors, including age and performance status, prior history of myelodysplasia or myeloproliferative disorders, prior exposure to cytotoxic agents or radiotherapy and, importantly, cytogenetic and molecular risk factors.4,5 Cytogenetic and molecular mutations are detectable in approximately 50–60% of newly diagnosed AML cases and confer survival outcomes that are categorized into favourable, intermediate and poor-risk groups according to the European Leukemia Net criteria.5,6 These criteria were determined based on outcomes from those receiving intensive therapy, mostly in individuals below 60 years of age. The mutational spectrum of older patients with AML (>60 years) varies drastically compared with individuals below 60 years. The incidence of TET2, DNMT3A, SRSF2, ASXL1, TP53 and SF3B1 is higher, indicating that these genes were associated with age-related haematopoiesis.7 A higher incidence of isocitrate dehydrogenase (IDH) mutations is also reported in older patients, which is a strong genetic predictor for shorter survival.8 However, with the advent of IDH inhibitors, the adverse impact of this mutation has become less clear. Thus, older patients are more likely to have more comorbidities, worse performance status, higher likelihood of preceding myeloid dysplastic syndrome (MDS) features and high-risk cytogenetic and molecular risk features, and have lower response rates as seen in response to intensive induction chemotherapy 40–60% in patients >60 years versus 60–85% in patients ≤60 years.9,10 Although patients with intermediate and high-risk cytogenetics are referred for consolidation with allogeneic haematopoietic stem cell transplantation (HSCT), older and more frail patients are often deemed ineligible due to risk of transplant-related mortality or higher risk of relapse with reductions in conditioning intensity. Thus, novel immunotherapies and approaches to cell therapy have emerged to address this unmet need.
- [Durvalumab for the Treatment of Advanced Biliary Tract Cancer](https://touchoncology.com/gastrointestinal-cancers/journal-articles/durvalumab-for-the-treatment-of-advanced-biliary-tract-cancer/): Despite being considered a rare type of malignancy, constituting only 3% of all gastrointestinal cancers, the incidence of biliary tract cancers (BTCs) has been increasing worldwide in recent years, with about 20,000 new cases annually only in the USA.1–3 These cancers arise from the biliary epithelium of the small ducts in the periphery of the liver (intrahepatic) and the main ducts of the hilum (extrahepatic). Extrahepatic BTCs include gallbladder cancer and cancers of the common bile duct. Although extrahepatic cancers arise from similar epithelia, their aetiology can differ significantly due to their anatomical variations.4 Risk factors vary depending on the origin and include chronic viral infections (such as hepatitis B and C) as well as chronic inflammation of the liver and biliary tract (cirrhosis, fibrosis, diabetes, alcoholism, obesity, tobacco use, primary sclerosing cholangitis, hepatolithiasis and Caroli’s disease).3,4
- [ROSEWOOD Trial: A Landmark Trial in the Treatment of Relapsing/Remitting Follicular Lymphoma](https://touchoncology.com/hematologic-malignancies/journal-articles/rosewood-trial-a-landmark-trial-in-the-treatment-of-relapsing-remitting-follicular-lymphoma/): Bruton tyrosine kinase (BTK) plays a functional and integral role in B-cell receptor (BCR) signalling and is expressed in normal and malignant B cells. Given BTK’s central role in the survival and proliferation of malignant B cells, BTK inhibitors have been developed for use in various B-cell malignancies, with several US Food and Drug Administration approvals in chronic lymphocytic leukaemia (CLL), mantle cell lymphoma, marginal zone lymphoma and Waldenstrom macroglobulinaemia/lymphoplasmacytic lymphoma.1 BTK inhibitors provide targeted, effective and less toxic treatment options for patients compared with traditional chemotherapy regimens. Next-generation BTK inhibitors, such as acalabrutinib and zanubrutinib, are more selective and have fewer side effects than ibrutinib. Despite the success of BTK inhibitors in these lymphomas, their efficacy in relapsed/refractory (R/R) follicular lymphoma (FL) has historically been limited.
- [Foreword – touchREVIEWS in Oncology & Haematology, Volume 20, Issue 2, 2024](https://touchoncology.com/breast-cancer/journal-articles/foreword-touchreviews-in-oncology-haematology-volume-20-issue-2-2024/): We open with an editorial by Mohammad Ammad Ud Din and colleagues, exploring the role of online public interest as a marker of health awareness. Their study on breast cancer search trends in Pakistan offers a unique perspective on how digital tools can amplify the reach and effectiveness of public health campaigns.
- [Mesothelioma and Immunotherapies](https://touchoncology.com/lung-cancer/journal-articles/mesothelioma-and-immunotherapies/): The results of prospective clinical trials for single-agent immune checkpoint inhibitors (ICIs) in pleural mesothelioma have been somewhat inconsistent, but they have shown some possible survival advantages. This may be related to the heterogeneous nature of mesothelioma or unidentified biological differences that could predict the benefit of ICIs (see the sections on ‘Randomized immunotherapy trials of mesothelioma’ and ‘Predictors of response to immune checkpoint inhibitors’).
- [Redefining Treatment Paradigms in Metastatic Castration-resistant Prostate Cancer: A Comprehensive Analysis of Cabozantinib and Atezolizumab Based on the CONTACT-02 Study Results](https://touchoncology.com/prostate-cancer/journal-articles/redefining-treatment-paradigms-in-metastatic-castration-resistant-prostate-cancer-a-comprehensive-analysis-of-cabozantinib-and-atezolizumab-based-on-the-contact-02-study-results/): The rationale for integrating cabozantinib into the therapeutic regimen for advanced PCa is built by its multi-targeted mechanism that aligns well with the pathology of mCRPC. The inhibition of MET and VEGFR not only impacts tumour growth and vascularization but also addresses the bone metastases that frequently complicate PCa progression.25,26 By disrupting these pathways, cabozantinib could theoretically reduce tumour viability and metastatic spread, crucial outcomes for patients with mCRPC who often face limited treatment options. Moreover, the drug’s ability to modulate the immune environment, enhancing the efficacy of immunotherapies, presents an innovative approach to treatment, potentially overcoming some of the traditional resistances encountered with other therapies.27 Clinical and preclinical studies support the application of cabozantinib in PCa, showing promising results in tumour regression and inhibition of angiogenesis, thus providing a compelling case for its use in advanced stages of the disease.28,29 Randomized trials, however, have been unable to demonstrate significant incremental efficacy over the standard of care in mCRPC. The CONTACT-02 study (‘A Study of Cabozantinib in Combination with Atezolizumab Versus Second Novel Hormonal Therapy in Subjects with Metastatic Castration-resistant Prostate Cancer’; ClinicalTrials.gov identifier: NCT04446117) evaluated cabozantinib plus atezolizumab in comparison with a second novel hormonal therapy (NHT) in chemo-naive mCRPC.
- [Advancements in Immune Checkpoint Inhibitors for Oesophageal Squamous Cell Carcinoma: Current Status and Future Perspectives](https://touchoncology.com/gastrointestinal-cancers/journal-articles/advancements-in-immune-checkpoint-inhibitors-for-oesophageal-squamous-cell-carcinoma-current-status-and-future-perspectives/): Oesophageal cancer is the eighth most commonly diagnosed cancer and is the sixth leading cause of cancer death worldwide.1,2 Worldwide, around 604,100 new instances of oesophageal cancer were recorded in 2020, leading to approximately 544,100 deaths. This translates to a standardized incidence rate of 6.3 per 100,000 people and a mortality rate of 5.6 per 100,000. The majority of cases, about 85%, were oesophageal squamous cell carcinomas (ESCCs), totalling approximately 512,500 cases. Notably, men experienced incidence and mortality rates approximately two to three times higher than those of women. There were significant disparities in incidence and mortality rates across different regions globally, with Eastern Asia and Southern and Eastern Africa, where ESCC is the most common histology, exhibiting the highest rates. Projections suggest that if these rates remain constant, the year 2040 could see approximately 957,000 new cases of oesophageal cancer, comprising 806,000 ESCC cases.3
- [Advances in Targeting KRAS G12C in Gastrointestinal Malignancies: Focus on KRAS G12C Inhibitors](https://touchoncology.com/gastrointestinal-cancers/journal-articles/advances-in-targeting-kras-g12c-in-gastrointestinal-malignancies-focus-on-kras-g12c-inhibitors/): Rat sarcoma virus (RAS) proteins are a family of prototypical oncogenes frequently mutated in human cancers. Mutations in the RAS gene account for 19% of all pathogenic alterations and are the subject of extensive research in molecular and clinical oncology.1 The RAS family consists of three major isoforms, namely the Harvey rat sarcoma virus (HRAS), the neuroblastoma RAS viral oncogene homologue (NRAS) and the Kirsten rat sarcoma virus (KRAS). Amongst these, KRAS is the most frequently mutated of the RAS isoforms, with a remarkably high mutational prevalence in gastrointestinal (GI) malignancies, including 90% of pancreatic ductal adenocarcinomas (PDAC) and 50% of colorectal cancers (CRC).2 The high prevalence of KRAS aberrations in GI malignancies was crucial in promoting studies that identified KRAS’s central role as an oncogenic driver and a critical factor in resistance against cytotoxic chemotherapy.3 However, despite decades of research into its molecular configuration, efforts in targeting KRAS have been elusive for several reasons: the absence of deep pockets in the RAS protein, making it inaccessible to small-molecule inhibitors, the constant transition between two distinct conformational states with vastly different chemical behaviours and the high affinity for guanosine-5'-triphosphate (GTP), allowing the KRAS protein to function despite low GTP concentrations, have made the design of a targeted KRAS inhibitor particularly difficult.4
- [Trifluridine/Tipiracil and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer](https://touchoncology.com/colorectal-cancer/journal-articles/trifluridine-tipiracil-and-bevacizumab-in-adults-with-refractory-metastatic-colorectal-cancer/): The rationale for combining trifluridine and tipiracil lies in their synergistic pharmacological effect: tipiracil enhances the bioavailability of trifluridine by inhibiting its breakdown.5 Studies have shown that combining trifluridine/tipiracil with an anti-angiogenic agent that targets vascular endothelial growth factor (VEGF) (bevacizumab ) can lead to augmented intracellular concentrations of active trifluridine, as demonstrated in preclinical studies.6 This combination has been extensively studied, with clinical trials reporting promising results regarding the efficacy and safety in patients with refractory mCRC.7
- [Gauging the Online Public Interest in Breast Cancer in Pakistan](https://touchoncology.com/breast-cancer/journal-articles/gauging-the-online-public-interest-in-breast-cancer-in-pakistan/): The incidence rate of breast cancer (BC) is the highest in Pakistan among all Asian countries.1 In 2018 alone, 2.1 million cases were diagnosed, although the exact number is likely much higher due to poor reporting in rural areas and the lack of a formal national cancer registry.1,2 Over the last decade, multiple non-governmental organizations and large cancer care institutions have led mass media campaigns to raise awareness regarding BC to improve screening and early detection.1,3,4 Web-based surveillance of online search activity is an emerging metric to assess the effectiveness of such endeavours. Recent studies have shown a strong relationship between health campaigns and information-seeking behaviours, suggesting that infoveillance can measure the success of such public health drives.5,6 Our study determines the online public activity related to BC in Pakistan over the last decade. We hypothesize that the data regarding search queries may be correlated with the collective interest of the population in the disease.
- [A Comprehensive Review of the Growing Landscape of Endocrine and Biologic Treatments for Hormone Receptor-positive Breast Cancer](https://touchoncology.com/breast-cancer/journal-articles/a-comprehensive-review-of-the-growing-landscape-of-endocrine-and-biologic-treatments-for-hormone-receptor-positive-breast-cancer/): Endocrine therapy (ET) has changed the natural history of hormone receptor-positive (HR+) breast cancer (BC) and is the cornerstone of the treatment of HR+ BC. There are several ETs approved for the treatment of BC, including selective oestrogen receptor modulators (SERMs; tamoxifen), aromatase inhibitors (AIs; anastrazole, letrozole and exemestane) and selective oestrogen receptor degraders (SERDs; fulvestrant and elacestrant).1–3 Additionally, several targeted agents have been approved, including cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), protein kinase B (AKT) inhibitors, phosphoinositide 3-kinase (PIK3CA) and mammalian target of rapamycin (mTOR) inhibitors, which have been shown to improve patient outcomes when given in combination with ET.4–9
- [Foreword – touchREVIEWS in Oncology & Haematology, Volume 20, Issue 1, 2024](https://touchoncology.com/breast-cancer/journal-articles/foreword-touchreviews-in-oncology-haematology-volume-20-issue-1-2024/): Welcome to the latest issue of touchREVIEWS in Oncology & Haematology. We are honoured to present a series of compelling articles that reflect cutting-edge developments and diverse perspectives in this ever-evolving field. This issue includes a series of editorials and reviews from esteemed experts who provide insights into novel therapies and their potential to change clinical practices in oncology and haematology.
- [Trastuzumab Deruxtecan for the Treatment of HER2-low Advanced or Metastatic Breast Cancer](https://touchoncology.com/breast-cancer/journal-articles/trastuzumab-deruxtecan-for-the-treatment-of-her2-low-advanced-or-metastatic-breast-cancer/): Trastuzumab deruxtecan (T-DXd) is a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody–drug conjugate (ADC) designed to effectively deliver a potent topoisomerase I inhibitor (exatecan derivative) to HER2-expressing cancer cells and limit potential systemic toxicity.1 T-DXd has shown remarkable efficacy against recurrent HER2-positive breast cancer in many trials.2–5 This payload, an exatecan derivative, is highly active among camptothecins and linked to the humanized anti-HER2 antibody by a peptide-based linker that is stable in the plasma and cleaved by lysosomal cathepsins, whose expression is increased in cancer cells.6 After cleavage, the released drug is permeable to the cell membrane, allowing the released payload to have a bystander effect on the neighbouring tumour cells, regardless of the HER2 expression status.7 The antitumour activity in HER2-low tumours may be due to the combination of the bystander effect and a high drug-to-antibody ratio of T-DXd.7,8
- [A New Frontier in the Treatment of Epidermal Growth Factor Receptor-mutated Non–Small-Cell Lung Cancer: Amivantamab-vmjw and Chemotherapy](https://touchoncology.com/lung-cancer/journal-articles/a-new-frontier-in-the-treatment-of-epidermal-growth-factor-receptor-mutated-non-small-cell-lung-cancer-amivantamab-vmjw-and-chemotherapy/): Following exon 19 deletions and exon 21 L858R mutations, EGFR exon 20 insertions represent the third most common type of EGFR mutations, accounting for 4–10% of all EGFR mutations.2 In contrast to the classical activating EGFR mutations, EGFR exon 20 insertions are consistently associated with de novo resistance to clinically approved EGFR-TKIs, including osimertinib.3 Therefore, the recommended first-line treatment is platinum-doublet chemotherapy in spite of poor outcomes; the overall response rate (ORR) is 19%, and the median progression-free survival (mPFS) remains under 6 months.4 Based on the phase I CHRYSALIS study (A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer; ClinicalTrials.gov identifier: NCT02609776), amivantamab-vmjw is now approved in pretreated patients with NSCLC harbouring EGFR exon 20 insertion mutations.1,5
- [Dostarlimab for the Treatment of Endometrial Cancer: A Review](https://touchoncology.com/gynecologic-cancers/journal-articles/dostarlimab-for-the-treatment-of-endometrial-cancer-a-review/): The use of immune checkpoint inhibitors, such as dostarlimab, pembrolizumab, durvalumab and atezolizumab, has been studied in patients with endometrial cancer across the molecular classification spectrum and has shown significant promise in dMMR tumours and limited efficacy in microsatellite-stable tumours. These new therapies are leading to the approval by the US Food and Drug Administration (FDA) and National Comprehensive Cancer Network-listed treatments for patients with endometrial cancer. For example, dostarlimab is now approved by the FDA for dMMR endometrial cancer as both a single agent for the second line or greater and in conjunction with platinum-based chemotherapy as the first line in newly diagnosed advanced-stage or recurrent chemotherapy-naive settings.4
- [Long-term Survival in Patients with Advanced Hepatocellular Cancer with Dual Immunotherapy Agents: Tremelimumab Plus Durvalumab](https://touchoncology.com/gastrointestinal-cancers/journal-articles/long-term-survival-in-patients-with-advanced-hepatocellular-cancer-with-dual-immunotherapy-agents-tremelimumab-plus-durvalumab/): For more than a decade, sorafenib, a multikinase inhibitor, was the only systemic therapeutic option that had demonstrated improved overall survival (OS) in advanced HCC and received US Food and Drug Administration approval in 2007.6,7 In the last 5 years, multiple therapies have been approved in the first-line setting, including another multikinase inhibitor, lenvatinib; a combination of programmed death-1 and vascular endothelial growth factor, atezolizumab plus bevacizumab and a combination of programmed cell death ligand 1, and cytotoxic T lymphocyte-associated antigen 4 inhibitor, durvalumab plus tremelimumab.8–10 Results from clinical trials evaluating the combination of immunotherapy and tyrosine kinase have been disappointing so far. However, until recently, the impact of systemic therapy on long-term survival in patients with advanced HCC remains unclear.
- [Futibatinib for the Treatment of Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 (FGFR2) Gene Fusions or Other Rearrangements](https://touchoncology.com/gastrointestinal-cancers/journal-articles/futibatinib-for-the-treatment-of-previously-treated-unresectable-locally-advanced-or-metastatic-intrahepatic-cholangiocarcinoma-with-fibroblast-growth-factor-receptor-2-fgfr2-gene-fusions-or-other/): Cholangiocarcinoma (CCA) is a cancer of the epithelial cells lining the biliary tree in the liver and can occur both inside the liver (intrahepatic CCA ) and outside the liver (extrahepatic CCA, which includes both perihilar and distal cholangiocarcinoma) (Figure 1).
- [Fruquintinib in Patients with Previously Treated Metastatic Colorectal Cancer](https://touchoncology.com/colorectal-cancer/journal-articles/fruquintinib-in-patients-with-previously-treated-metastatic-colorectal-cancer/): Outcomes for patients with metastatic colorectal cancer have steadily improve due to discovery of new drugs as well as increasing number patients undergoing local therapies.1 Angiogenesis is of a paramount importance in this disease and since vascular endothelial growth factor (VEGF) discovery several drugs targeting this pathway have been developed.2,3
- [Immunotherapeutic Advances in the Treatment of Merkel Cell Carcinoma](https://touchoncology.com/dermatologic-cancers/journal-articles/immunotherapeutic-advances-in-the-treatment-of-merkel-cell-carcinoma/): Merkel cell carcinoma (MCC) is a rare, poorly differentiated and highly aggressive neuroendocrine cutaneous cancer with a high propensity to grow rapidly and metastasize early. Merkel cell polyomavirus (MCPyV) is now estimated to be the causative factor in up to 80% of MCC cases.1 Meanwhile, the remaining 20% are attributed to significant exposure to ultraviolet radiation.2 The incidence of MCC in the USA is rising, with an estimated rate of 3,000 cases per year in 2025.3,4 This trend has been ascribed to improved diagnostic methods, an ageing population, increased overall sun exposure and the rising number of immunosuppressed patients.5
- [Olutasidenib for Adults with Relapsed or Refractory Acute Myeloid Leukaemia with Isocitrate Dehydrogenase 1 Mutation](https://touchoncology.com/leukemia/journal-articles/olutasidenib-for-adults-with-relapsed-or-refractory-acute-myeloid-leukaemia-with-isocitrate-dehydrogenase-1-mutation/): Acute myeloid leukaemia (AML) is a rare aggressive haematological malignancy characterized by aberrant differentiation and overproliferation of non-functional myeloid precursor cells that will accumulate in the bone marrow, blood and, occasionally, other tissues.1–5 The prognosis of AML remains poor, especially in older/unfit patients and in the case of patients with relapsed or refractory (R/R) diseases.2,6
- [Foreword – touchREVIEWS in Oncology & Haematology, Volume 19, Issue 2, 2023](https://touchoncology.com/breast-cancer/journal-articles/foreword-touchreviews-in-oncology-haematology-volume-19-issue-2-2023/): In the latest edition of touchREVIEWS in Oncology & Haematology, we are pleased to present a collection of articles that delve into the latest research and advancements in the field. From innovative therapies and genetic treatments to analyses of digital patient education tools, each article contributes to our evolving understanding of complex medical conditions, offering new perspectives and highlighting the progress being made in these fields.
- [Cell-based Genetic Therapy for the Induction of Foetal Haemoglobin in Sickle Cell Disease and Transfusion-dependent β-thalassaemia](https://touchoncology.com/hematology/journal-articles/cell-based-genetic-therapy-for-the-induction-of-foetal-haemoglobin-in-sickle-cell-disease-and-transfusion-dependent-%ce%b2-thalassaemia/): Haemoglobin gene expression switches during progression from embryo to foetus to adult. The switch starts midway through gestation as HbF production falls and HbA production increases. It is normally complete within months after birth. In normal adults, HbF constitutes
- [Findings from the XTEND-Kids Study: Efanesoctocog Alfa for Severe Haemophilia A in Children](https://touchoncology.com/hematology/journal-articles/findings-from-the-xtend-kids-study-efanesoctocog-alfa-for-severe-haemophilia-a-in-children/): Severe haemophilia A (HA), defined as baseline factor VIII (FVIII) levels of
- [Temozolomide for Paediatric High-Grade Glioma: Time for a Rethink?](https://touchoncology.com/neuro-oncology/journal-articles/temozolomide-for-paediatric-high-grade-glioma-time-for-a-rethink/): The management of children with diffuse midline gliomas (DMG) and other paediatric high-grade gliomas (pHGG) continue to present one of the most difficult challenges facing paediatric oncologists, characterized by poor patient outcomes.1 Standard of care therapy, which includes a maximal safe resection where possible, followed by focal radiation therapy, has remained unchanged for decades. This therapy, however, is essentially palliative in nature, as despite all efforts, there is no known curative treatment. Temozolomide (TMZ) is an oral alkylating agent that is generally well tolerated and can be used in combination with radiation therapy and as maintenance therapy. TMZ has been shown to improve survival in adult high-grade glioma (HGG), leading to its integration into some pHGG protocols.2–4 However, its benefit in pHGG remains unclear, and its role needs re-evaluation, as there is limited evidence of survival benefit and well documented toxicity. The 2021 fifth edition of the World Health Organization (WHO) Classification of Tumors of the Central Nervous System advances the role of molecular alterations in diagnostics and tumour classification, labelling gliomas as ‘adult-type’ or ‘paediatric-type’, highlighting the fact that active treatments in the adult setting may not necessarily translate to paediatric tumours.5,6
- [Zolbetuximab: An Investigational First-Line Treatment for CLDN18.2-positive, HER2-negative Gastric and Gastro-oesophageal Junction Cancer](https://touchoncology.com/gastrointestinal-cancers/journal-articles/zolbetuximab-an-investigational-first-line-treatment-for-cldn18-2-positive-her2-negative-gastric-and-gastro-oesophageal-junction-cancer/): The backbone of first-line treatment in gastric/GOJ cancer is a combination of platinum and fluoropyrimidine chemotherapeutic agents.4,5 The ToGA trial (ClinicalTrials.gov identifier: NCT01041404), published in 2010, found that the addition of trastuzumab adds a modest survival benefit for patients with human epidermal growth factor receptor 2 (HER2)-positive tumours.6 However, despite this advance, nearly a decade passed before the next step forward in the treatment of these cancers.7 These new approaches included immunotherapy and targeted agents such as immune checkpoint inhibitors, fibroblast growth factor receptor 2 (FGFR2b) blockers, and antibody–drug conjugates (fam-trastuzumab deruxtecan-nxki ; Daiichi Sankyo, Inc, Basking Ridge, NJ, USA).8 In addtion to these, agents that target Claudin 18.2 (CLDN18.2) are also under intense investigation for treating gastic/GOJ tumors.9
- [Quality and Reliability of Spanish-language YouTube Videos on Breast Cancer](https://touchoncology.com/breast-cancer/journal-articles/quality-and-reliability-of-spanish-language-youtube-videos-on-breast-cancer/): Breast cancer is the leading cause of cancer death in Hispanic women in the USA. According to the American Cancer Society, as many as one in nine Hispanic women will develop invasive breast cancer during their lifetime and one in 49 Hispanic women will die from invasive breast cancer.1 Female breast cancer is also the most common and leading cause of cancer death in Latin American and Caribbean countries, with an estimated 114,900 new diagnoses and 37,000 deaths each year.2,3
- [Targeting Mutant IDH to Treat Low-grade Glioma](https://touchoncology.com/neuro-oncology/journal-articles/targeting-mutant-idh-to-treat-low-grade-glioma/): Adult-type diffuse low-glade gliomas (LGGs) (World Health Organization grade 2) represent 5–10% of all primary brain tumours.1 The median age of onset is in the third and fourth decades of life. Common clinical presentations include seizures, focal neurological deficits, and new-onset headaches.2 Magnetic resonance imaging (MRI) demonstrates T1 signal hypointensity and T2/fluid attenuated inversion recovery (FLAIR) hyperintensity with occasional enhancement. They tend to develop in the frontal or temporal lobes; however, all lobes of the brain can harbor these tumours.2 Traditionally, LGG pathology was described in terms of histological appearance. With the updates to WHO 2021 classification for central nervous system tumours, LGG pathology is defined not only by the histology, but also by the molecular/genetic makeup of the tumour.3 The most important genetic aberration that defines adult-type diffuse LGG is mutations in the isocitrate dehydrogenase (IDH) gene.4 IDH has two isoforms, IDH1 in the cytoplasm and IDH2 in the mitochondria, with the most common mutation being the IDH1 mutation in the 132 codon from arginine to histidine (Figure 1).5,6 The normal IDH enzyme is part of the Krebs cycle and converts isocitrate to α-ketoglutarate. When the IDH1/2 mutant enzyme is present, α-ketoglutarate is converted to 2-hydroxyglutarate, the oncometabolite responsible for gliomagenesis.7 The observation is that all glial tumours with IDH mutations have an improved prognosis compared with those with IDH wildtype genotype, and this was the key motivation to make these specific categories in WHO 2021 classification system. Adult-type LGGs WHO grade 2 are currently described as oligodendroglioma, IDH-mutant, and 1p/19q-deleted and astrocytoma, IDH-mutant. 1p/19q co-deletion involves complete deletion of the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q) and is specific to oligodendrogliomas (Table 1). Moreover, it is a predictive and prognostic biomarker in patients with oligodendroglioma as patients respond better to combinatorial chemotherapy and have a better prognosis.8,9
- [Incorporation of Combination Immunotherapy into the Treatment Paradigms of Gastrointestinal Cancers](https://touchoncology.com/gastrointestinal-cancers/journal-articles/incorporation-of-combination-immunotherapy-into-the-treatment-paradigms-of-gastrointestinal-cancers/): The field of immuno-oncology has provided novel therapeutic agents that have led to significant improvements in patient outcomes across many tumour types. There have also been great efforts to incorporate immunotherapy (IO) into the treatment paradigms of gastrointestinal (GI) cancers. Across GI tumour types, enhanced efficacy has been seen when these agents are used in combination with other IO agents, chemotherapy and targeted drugs, and when introduced during earlier lines of treatment and in earlier cancer stages. There are ongoing efforts to select patients who are more likely to benefit from these treatments, further investigate the use of these agents in earlier stages of the disease, and enhance the likelihood and durability of response. This review will summarize the recent updates in standard practice that incorporate IO into the management of GI cancers. It will also highlight ongoing clinical studies with the potential to change standard practice.
- [Sacituzumab Govitecan for the Treatment of HR+/HER2- Breast Cancer in Heavily Pre-treated Patients](https://touchoncology.com/breast-cancer/journal-articles/sacituzumab-govitecan-for-the-treatment-of-hr-her2-breast-cancer-in-heavily-pre-treated-patients/): Breast cancer is the most common cancer among women worldwide, and more than a fifth of those diagnosed will develop incurable metastatic disease.1 Molecular testing to investigate genetic and genomic variation is essential to identify the most effective treatment plans for patients. Treatment options available for patients with breast cancer are directed through the receptor status – hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) – with the most common phenotype being HR positive (HR+) HER2 negative (HER2-).2–4
- [Teclistamab Monotherapy for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma](https://touchoncology.com/hematologic-malignancies/journal-articles/teclistamab-monotherapy-for-the-treatment-of-adult-patients-with-relapsed-and-refractory-multiple-myeloma/): Successful adaptive immune redirection has also been shown with bispecific antibodies (BsAbs) against various established and emerging MM cell targets. This review follows the US Food and Drug Administration (FDA) approval of teclistamab – the first-in-kind commercially available BsAb for RRMM.12 Teclistamab is a T cell-redirecting antibody that targets CD3 on the surface of T cells and BCMA expressed on the surface of myeloma cells (BCMA×CD3). It was approved for use as monotherapy in 2022 based on data from the MajesTEC-1 trial published in June 2022.13 Teclistamab and similar agents in development enable T cell redirection with similar potency to CAR T cells but without the delay required for patient-specific manufacturing.
- [Foreword – touchREVIEWS in Oncology & Haematology, Volume 19, Issue 1, 2023](https://touchoncology.com/gastrointestinal-cancers/journal-articles/foreword-touchreviews-in-oncology-haematology-volume-19-issue-1-2023/): Welcome to the latest edition of touchREVIEWS in Oncology & Haematology, which features some of the recent key developments in oncological and haematological disease. The journal opens with an expert interview with Linda Martin on a new fluorescent imaging agent for lung cancer detection. Screening using conventional methods is challenging but the results from the ELUCIDATE trial (ClinicalTrials. gov identifier: NCT04241315) indicate potential for improved disease screening for those with known or suspected lesions. Following this, David Ziegler provides an editorial on a new targeted treatment approach for paediatric low-grade gliomas using pan-RAF inhibitors, with promising early results raising the prospect of a new standard of care therapy for the most common childhood brain tumour.

## Pages
- [EAU](https://touchoncology.com/eau/)
- [ESMO](https://touchoncology.com/esmo-2/)
- [Your Path to Better Medical Knowledge Starts Here – FREE Registration!](https://touchoncology.com/your-free-10-minutes-at-a-time-medical-education-google/): Become part of a global network of healthcare professionals enhancing patient outcomes with FREE access to our mobile-friendly medical education platform. Stay up-to-date with the latest scientific advancements, delivered in concise formats, so you can learn anytime, anywhere, at your own pace.
- [Learning Activities](https://touchoncology.com/learning-activities/)
- [sharing perspectives specific dees through the lens of a paediatric and an adult neurologist](https://touchoncology.com/sharing-perspectives-specific-dees-through-the-lens-of-a-paediatric-and-an-adult-neurologist2/)
- [Saved Activities](https://touchoncology.com/my-learning/saved-activities/)
- [Subscriptions & Interests](https://touchoncology.com/my-learning/subscriptions-interests/)
- [Account Settings](https://touchoncology.com/my-learning/account-settings/)
- [My Learning](https://touchoncology.com/my-learning/)
- [Your Path to Better Medical Knowledge Starts Here – FREE Registration!](https://touchoncology.com/your-free-10-minutes-at-a-time-medical-education/): Become part of a global network of healthcare professionals enhancing patient outcomes with FREE access to our mobile-friendly medical education platform. Stay up-to-date with the latest scientific advancements, delivered in concise formats, so you can learn anytime, anywhere, at your own pace.
- [test page](https://touchoncology.com/test-page/)
- [touchPANEL DISCUSSION – Head and Neck Cancer (HNSCC) thank you page](https://touchoncology.com/thank-you-questions/): Many thanks for your submission, we will be in contact with you when this activity is available to watch. Please feel free to check our further content on our site.
- [touchPANEL DISCUSSION – Head and Neck Cancer (HNSCC) submission form](https://touchoncology.com/touchpanel-discussion-head-and-neck-cancer-hnscc/)
- [Certification Download](https://touchoncology.com/certification-download/)
- [Thank You](https://touchoncology.com/contact-us/thank-you/): Thanks - our team will be in touch soon!
- [Thank You](https://touchoncology.com/order-reprints/thank-you/): Thank you for your enquiry, our team will be in touch soon.
- [Editorial Board](https://touchoncology.com/editorial-board/): Introducing the Editorial Board of touchREVIEWS in Oncology & Haematology, who support our mission to advance medical knowledge and practice by ensuring the integrity, relevance, and impact of the content we publish. Together, we strive to foster a vibrant academic community and contribute to the continuous improvement of healthcare worldwide.
- [Sitemap](https://touchoncology.com/sitemap/)
- [Press Releases](https://touchoncology.com/press-releases/)
- [Account Created](https://touchoncology.com/account-created/)
- [Journals](https://touchoncology.com/journal-articles/)
- [Specialities](https://touchoncology.com/specialities/)
- [CME](https://touchoncology.com/cme/): test
- [touchCONGRESS](https://touchoncology.com/ovarian-cancer/)
- [touchCONGRESS](https://touchoncology.com/multiple-myeloma/)
- [touchCONGRESS](https://touchoncology.com/asco20-virtual/)
- [Curriculum Zone](https://touchoncology.com/curriculum-zone-advanced-breast-cancer/)
- [touchCONGRESS](https://touchoncology.com/touchcongress-metex14-non-small-cell-lung-cancer/)
- [touchCONGRESS](https://touchoncology.com/touchcongress-egfr-non-small-cell-lung-cancer/)
- [Curriculum Zone](https://touchoncology.com/curriculum-zone/)
- [Password Reset](https://touchoncology.com/password-reset/)
- [Education Zone](https://touchoncology.com/education-zone/)
- [touchREVIEWS in Oncology & Haematology](https://touchoncology.com/oncology-journals/): INFORMATION FOR AUTHORS
- [Society & Congress Partners](https://touchoncology.com/society-partners/)
- [My Account](https://touchoncology.com/my-account/)
- [Create Account](https://touchoncology.com/create-account/)
- [Testimonials](https://touchoncology.com/testimonials/): touchONCOLOGY.com is a platform for the review articles, case reports, original contributions and technical reviews published in the journals European Oncology & Haematology and Oncology & Hematology Review, respectively.
- [Permissions](https://touchoncology.com/permissions/): We’ve partnered with Copyright Clearance Center (CCC) to make it easy for you to request permissions to reuse Touch Medical Media content. Do you want to send copies of an article to a client? Post a copy to the company Internet page? With copyright.com, you can quickly and easily secure the permissions you need. Simply follow these steps to get started:
- [Order Reprints](https://touchoncology.com/order-reprints/): Your name Your email Enquiry Type
—Please choose an option—Journals articles & IssuesWork with usWork for usFeedback Your message (optional)
- [Login](https://touchoncology.com/login/)
- [Forgot Password](https://touchoncology.com/forgot-password/)
- [Article](https://touchoncology.com/article/)
- [About Us](https://touchoncology.com/about-us/): At touchONCOLOGY, we push the boundaries of online medical education to bring you innovative formats and valuable insights into learning behaviours. Our educational content enhances your ability to provide better patient care and drive positive change in clinical practice. With patients at the heart of everything we do, we aim to help you significantly improve health outcomes.
- [Home](https://touchoncology.com/)
- [Contact us](https://touchoncology.com/contact-us/): Your name Your email Enquiry Type
—Please choose an option—Journals articles & IssuesWork with usWork for usFeedback Your message (optional)

## Industry Insights
- [President Prof Benjamin Besse: Shaping the future of cancer research at EORTC](https://touchoncology.com/insight/president-prof-benjamin-besse-shaping-the-future-of-cancer-research-at-eortc/): As EORTC enters a new chapter under the Presidency of Professor Benjamin Besse (Gustave Roussy Institute and Paris-Saclay University, Villejuif, France), the organization is looking to accelerate academic research while keeping patients and scientific independence at its core. In this detailed and in-depth Q&A, Prof Besse shares his priorities for EORTC, from supporting the next generation of investigators and broadening clinical trial populations, to giving greater weight to quality of life and patient perspectives. He also considers how emerging technologies, including artificial intelligence, could reshape the way cancer research is conducted.
- [Distinguishing true progression from pseudoprogression in MGMT-methylated glioblastoma](https://touchoncology.com/insight/distinguishing-true-progression-from-pseudoprogression-in-mgmt-methylated-glioblastoma/): How can clinicians distinguish true progression from pseudoprogression in MGMT-methylated glioblastoma? Dr Jigisha Thakkar discusses the clinical implications of time to true progression in MGMT-methylated glioblastoma and approaches to distinguishing pseudoprogression from treatment failure.
- [Expert perspectives from WCLC 2026: B7-H3 ADCs, MRI surveillance and emerging targeted therapies](https://touchoncology.com/insight/expert-perspectives-from-wclc-2026-b7-h3-adcs-mri-surveillance-and-emerging-targeted-therapies/): Dr Igor Gómez-Randulfe Rodríguez examines four studies from WCLC 2026 that could influence the evolving management of small-cell lung cancer and molecularly defined non-small-cell lung cancer, from B7-H3 antibody-drug conjugates and MRI surveillance to emerging therapies targeting EGFR exon 20 insertions and ROS1.
- [Expert perspectives from WCLC 2026: Advances in SCLC, HER2-mutant and oncogene-driven NSCLC](https://touchoncology.com/insight/wclc-2026-what-the-latest-data-mean-for-lung-cancer-treatment/): The 2026 World Conference on Lung Cancer delivered several results with the potential to change clinical practice. My main takeaway was the speed at which effective options are multiplying in both small-cell lung cancer and molecularly defined non-small-cell lung cancer. The immediate advance is welcome, but it also makes treatment selection more complex: mature survival, intracranial control, toxicity, sequencing and access will increasingly matter as much as response rate or progression-free survival.
- [The future of supportive cancer care: Insights from MASCC/ISOO 2026](https://touchoncology.com/insight/the-future-of-supportive-cancer-care-insights-from-mascc-isoo-2026/): From AI and real-time toxicity monitoring to exercise and behavioural interventions, Prof Joanne Bowen explores the innovations reshaping supportive cancer care and outlines MASCC’s priorities for translating emerging evidence into meaningful improvements for patients.
- [AIEOP-BFM ALL 2017: Can immunotherapy replace chemotherapy in pediatric ALL?](https://touchoncology.com/insight/aieop-bfm-all-2017-can-immunotherapy-replace-chemotherapy-in-pediatric-all/): The AIEOP-BFM ALL 2017 trial represents one of the clearest demonstrations to date that frontline immunotherapy can outperform and out-safeguard conventional chemotherapy in pediatric ALL. Beyond its immediate implications for high-risk disease, the study may provide the framework for broader treatment redesign across ALL risk groups, with future trials now focused on how far chemotherapy exposure can be safely reduced while preserving—and potentially improving—long-term cure. In this exclusive Q&A, Prof Martin Schrappe suggests this may be only the beginning of chemotherapy de-escalation in childhood ALL.
- [frontMIND marks first major frontline advance over R-CHOP in high-risk DLBCL in decades](https://touchoncology.com/insight/frontmind-marks-first-major-frontline-advance-over-r-chop-in-high-risk-dlbcl-in-decades/): For almost two decades, R-CHOP has remained the established frontline standard for DLBCL, yet approximately 40% of patients are not cured with first-line therapy. At EHA 2026, Prof Georg Lenz presented new phase 3 data from the frontMIND study suggesting that this long-standing backbone may now be open to improvement. The study showed that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival (PFS) in previously untreated patients with high-risk DLBCL and high-grade B-cell lymphoma (HGBL), marking one of the first positive frontline intensification trials in this setting in recent years.
- [Lymphoma at ASCO 2026: Six key abstracts](https://touchoncology.com/insight/lymphoma-at-asco-2026-six-key-abstracts/): Several important lymphoma studies presented at ASCO 2026 provided new data across newly diagnosed and relapsed/refractory disease settings. The studies spanned aggressive B-cell lymphomas and classic Hodgkin lymphoma, evaluating novel antibody-based combinations, epigenetic targeting strategies and chemotherapy-sparing approaches. Dr Tycel Phillips provides his expert insights into the six most important studies of the meeting.
- [Phase 3 SENTRY trial positions selinexor plus ruxolitinib as potential new frontline option in myelofibrosis](https://touchoncology.com/insight/phase-3-sentry-trial-positions-selinexor-plus-ruxolitinib-as-potential-new-frontline-option-in-myelofibrosis/): Late-breaking data from the phase 3 SENTRY trial show that selinexor plus ruxolitinib significantly improved spleen volume reduction in JAK inhibitor–naïve myelofibrosis, with rapid and sustained responses and an early signal for overall survival benefit. While symptom improvement was comparable to ruxolitinib alone, exploratory biomarker findings suggest potential disease-modifying activity, positioning the combination as a possible new frontline strategy.
- [EHA 2026 complete round-up: Discover the most important data across hematology](https://touchoncology.com/insight/eha-2026-complete-round-up-discover-the-most-important-data-across-hematology/): The European Hematology Association (EHA) 2026 Congress brought together the global hematology community to unveil the latest practice-shaping advances in hematological malignancies and blood disorders. From plenary and late-breaking trial results to prestigious award winners, novel therapeutics, translational science and emerging technologies, the meeting delivered a vast volume of data. In this expert-led round-up, leading specialists distil the most important data and key takeaways from across each disease area, offering an essential guide to the studies set to shape the future of hematology.
- [ASCO 2026 complete round-up: Discover the most important data by disease area](https://touchoncology.com/insight/asco-2026-complete-round-up-discover-the-most-important-data-by-disease-area/): touchONCOLOGY coverage of ASCO 2026
- [Circulating methylated SEPT9 and early HCC detection: Findings from SEPT9_CROSS](https://touchoncology.com/insight/circulating-methylated-sept9-and-early-hcc-detection-findings-from-sept9_cross/): At the European Association for the Study of the Liver (EASL) Congress 2026, Prof. Abderrahim Oussalah (University Hospital of Nancy, France), presented findings from the SEPT9_CROSS study (NCT03311152), a prospective, cross-sectional, diagnostic accuracy study evaluating circulating methylated SEPT9 (mSEPT9) as a biomarker for hepatocellular carcinoma (HCC) detection in patients with cirrhosis.1 The study explored the diagnostic performance of mSEPT9 alone and in combination with alpha-fetoprotein (AFP), with a particular focus on improving early-stage HCC detection. In this interview, Prof. Oussalah discusses the rationale behind the study, the key efficacy findings and the potential role of mSEPT9 in future HCC surveillance strategies.
- [INDIGO: Follow-up data supports sustained benefit of vorasidenib in IDH-mutant grade 2 glioma](https://touchoncology.com/insight/indigo-follow-up-data-supports-sustained-benefit-of-vorasidenib-in-idh-mutant-grade-2-glioma/): Extended follow-up from the phase 3 INDIGO trial presented at ASCO 2026 provides further evidence that vorasidenib may offer durable disease control in patients with grade 2 glioma harboring IDH1/2 mutations, reinforcing earlier findings that led to its regulatory approvals. In the article below, we provide a details analysis of the latest INDIGO data and Dr Timothy Cloughesy's expert perspective on what the longer-term efficacy and safety findings could mean for the evolving treatment landscape in IDH-mutant glioma.
- [Kidney cancer at ASCO 2026: The studies redefining the field](https://touchoncology.com/insight/kidney-cancer-at-asco-2026-the-studies-redefining-the-field/): From adjuvant immunotherapy to microbiome-driven precision medicine, the biggest renal cell carcinoma abstracts presented at ASCO 2026 highlight where the field is heading next, and what may change first. In this round-up, we discuss the key data from four of the meeting’s most important studies, from investigational to late-phase: RAMPART, KEYNOTE-564, CaboNivo in patients with nccRCC and microbiome-based predictive biomarker development in mRCC.
- [Bladder cancer at ASCO 2026: The breakthroughs that matter most](https://touchoncology.com/insight/bladder-cancer-at-asco-2026-the-breakthroughs-that-matter-most/): Bladder cancer’s treatment landscape is changing fast; and the biggest abstracts presented at ASCO 2026 show just how far that shift now extends. With insight from our Editor-in-Chief, Prof Axel S Merseburger (University Hospital Schleswig-Holstein, Germany), we examine the four studies likely to have the biggest impact on clinical practice across advanced and localized disease: EV-302, KEYNOTE-905, SAKK 06/19 and POTOMAC.
- [Prostate cancer at ASCO 2026: Which late-breakers could change practice?](https://touchoncology.com/insight/prostate-cancer-at-asco-2026-which-prostate-cancer-late-breakers-could-change-practice/): Landmark abstracts across localized and advanced prostate cancer presented at ASCO 2026 addressed treatment intensification, biomarker-driven therapy, radiotherapy modality comparisons, and novel radioligand strategies. In this piece we examine four studies that reflect important shifts in prostate cancer management, influencing both near-term treatment pathways and future: PROTEUS, TALAPRO-3, COMPPARE and ProstACT Global.
- [Gastrointestinal oncology at ASCO 2026: Six key late-breakers](https://touchoncology.com/insight/gastrointestinal-oncology-at-asco-2026-six-key-late-breakers/): Several late-breaking gastrointestinal oncology studies presented at ASCO 2026 highlighted how treatment selection is continuing to evolve across colorectal, hepatobiliary, gastric, and esophageal cancers, with new data on ctDNA-guided adjuvant therapy, earlier integration of targeted agents, and intensified perioperative strategies. In this round-up, we have selected six of the most important late-breakers, and examine the latest data from CIRCULATE, BREAKWATER, EMERALD-3, Neo-CRAG, SCIENCE, and RC48-C027.
- [ASCENT-04: Further data supports front-line sacituzumab govitecan for PD-L1-positive advanced triple-negative breast cancer](https://touchoncology.com/insight/ascent-04-sacituzumab-govitecan-mtnbc/): New ASCENT-04 data presented at ASCO 2026 suggest that first-line sacituzumab govitecan plus pembrolizumab may provide sustained clinical benefit beyond first progression in patients with previously untreated PD-L1-positive metastatic triple-negative breast cancer. The exploratory post-hoc analysis showed improved PFS2 versus chemotherapy plus pembrolizumab, despite high crossover to sacituzumab govitecan in the control arm.
- [Breast Cancer at ASCO 2026: Six key insights](https://touchoncology.com/insight/breast-cancer-at-asco-2026-six-key-insights/): Dr Rupert Bartsch (University of Vienna, Austria) highlighted six important studies across the breast cancer landscape presented at ASCO 2026. The studies below discuss interesting and strategic developments in genomic risk stratification in early disease, supportive care optimization, HER2-positive metastatic strategies and novel antibody–drug conjugates in triple-negative breast cancer.
- [Neuro-oncology at ASCO 2026: What did we learn?](https://touchoncology.com/insight/neuro-oncology-at-asco-2026-what-did-we-learn/): At ASCO 2026 several neuro-oncology presentations focused less on introducing entirely new paradigms and more on defining where existing and emerging therapies may best fit. Across brain metastases and glioma, phase 3 data addressed longstanding practical questions around radiation delivery, chemotherapy duration, and local therapies, while updated targeted therapy data in IDH-mutant glioma continued to mature. In this piece, Dr Rimas Lukas highlights four main abstracts from ASCO 2026, discussing their take-aways and considering their potential relevance for clinical practice.
- [Personalizing glioblastoma care through cultural understanding](https://touchoncology.com/insight/glioblastoma-cultural-understanding/): Glioblastoma (GBM) places an enormous emotional and practical burden on both patients and caregivers. At AAN 2026, Dr Jigisha Thakkar et al. explored how cultural and ethnic differences influence preferences for communication and care delivery in neuro-oncology settings. In this Q&A, Dr Thakkar discusses the key takeaways from her study, and how these findings could help shape more individualized approaches to neuro-oncologic care.
- [Dormancy in IDH-mutant gliomas: New insights into saltatory growth](https://touchoncology.com/insight/dormancy-in-idh-mutant-gliomas-new-insights-into-saltatory-growth/): At AAN 2026, Dr Jigisha Thakkar presented data challenging long-standing assumptions of continuous tumor growth and suggesting that some patients may benefit from more individualized surveillance and treatment strategies. In this Q&A, Dr Thakkar discusses how intermittent dormancy in IDH-mutant gliomas may influence clinical decision-making, from MRI surveillance intervals to the timing of therapeutic intervention.
- [Lung cancer at ASCO 2026: Key takeaways](https://touchoncology.com/insight/lung-cancer-asco-2026/): ASCO 2026 showed that thoracic oncology is moving beyond promising signals and increasingly closer to practice-changing evidence across multiple fields — from bispecific antibodies and ADC-based combinations to targeted therapy in both metastatic and peri-operative settings. In this piece, Dr Federico Monaca breaks down eight major abstracts from ASCO26, highlighting their take-aways and considering their potential relevance for clinical practice.
- [ASCO 2026 Plenary late-breaking abstracts: Key takeaways](https://touchoncology.com/insight/asco-2026-plenary-late-breaking-abstracts-key-takeaways/): The five selected Plenary late-breaking abstracts at the ASCO 2026 Annual Meeting in Chicago showcased some of the meeting’s most practice-influencing data. Across prostate cancer, sarcoma, lung cancer and pancreatic cancer, these phase 3 studies demonstrated meaningful improvements in survival outcomes, highlighting the growing impact of perioperative intensification, precision oncology and novel targeted therapies in difficult-to-treat disease settings.
- [SIOPE 2026 Highlights: Projects in Spotlight](https://touchoncology.com/insight/sp-siope-projects-in-spotlight/): At the 7th SIOP Europe Annual Meeting, the Projects in Spotlight sessions showcased the collaborative initiatives between SIOP Europe and key stakeholders. From innovation, rare malignancies and psychosocial support to survivorship, these projects aim to improve outcomes, coordination between research and clinical care, reduce inequalities, and strengthen patient-centred care across Europe. Scroll down for a snapshot of each project and click on the headings to find out more.
- [Inside SIOPE 2026: Key insights and late-breaking data](https://touchoncology.com/insight/sp-inside-siope-2026/): Congress coverage | This May, experts from around the world gathered in Glasgow, Scotland for the the 7th SIOP Europe Annual Meeting. This year celebrated the importance of collaboration,  bringing together the diverse stakeholders involved in facing children and adolescents with cancer, and ensuring all voices were heard. The Annual Meeting was held in partnership with CCI Europe, ensuring the representation and participation of childhood cancer parents and survivors.
- [The evolving future of paediatric oncology: from scientific advances to mentorship and digital innovation](https://touchoncology.com/insight/sp-young-siope-paediatric-oncology/): At the 7th SIOP Europe Annual Meeting, emerging therapies, biological precision, and workforce development are all under the spotlight. Dr Daniela Di Carlo (Chair, Young SIOPE), reflects on where the field is heading, particularly CAR T-cell therapy and artificial intelligence, and what is needed to ensure that progress translates into real-world benefit for children with cancer.
- [European Cancer Nursing Day 2026: Supporting life beyond cancer](https://touchoncology.com/insight/sp-european-cancer-nursing-day-2026/): Ahead of European Cancer Nursing Day 2026 (ECND26), Stavroula Chante (Macmillan Lead Cancer Nurse, The Royal Wolverhampton NHS Trust) discusses the growing importance of cancer nurses in survivorship care, personalised medicine and multidisciplinary oncology teams. Speaking about this year’s theme, 'Supporting Life Beyond Cancer', she highlights the increasing demands facing the oncology nursing workforce across Europe, the need for greater recognition and investment, and why supporting nurses is essential to improving patient outcomes and quality of life.
- [Listening to lived experience: How patient voices are reshaping paediatric oncology in Europe](https://touchoncology.com/insight/sp-lived-experience-paediatric-oncology-europe/): At the 7th SIOP Europe Annual Meeting, Anita Kienesberger (Chair, Childhood Cancer International Europe ), discusses the evolving landscape of paediatric oncology advocacy. She shares insights on the critical importance of psychosocial support, the necessity of collaborative research and the ongoing challenge of health inequalities across Europe. As CCI Europe transitions into an independent legal entity, Anita Kienesberger highlights the organisation's strategic shift toward empowering survivors and standardising long-term care.
- [Beyond borders: How ITCC is accelerating paediatric cancer trials across Europe](https://touchoncology.com/insight/sp-itcc-paediatric-cancer-trials-europe/): At the 7th SIOP Europe Annual Meeting, Professor Pamela Kearns (Emeritus Professor of Paediatric Oncology, University of Birmingham, UK and President, Innovative Therapies for Children and Adolescents with Cancer ) discusses how the ITCC consortium is reshaping access to cutting-edge treatments for children and adolescents across Europe and beyond. Prof Kearns leads a network spanning dozens of specialist centres, working to accelerate clinical trials, embed precision medicine and reduce inequities in access to innovation.
- [Measuring what matters: How PROMS are transforming paediatric oncology trials](https://touchoncology.com/insight/sp-measuring-what-matters-paediatric-oncology/): At the 7th SIOP Europe Annual Meeting, attention turned toward how children and families experience cancer treatment, not just how they respond clinically. One of the leading voices in this field is Professor Martha Grootenhuis (Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands). Her work focuses on integrating patient reported outcome measures (PROMS) into both clinical trials and routine care. In this Q&A, she discusses the key take-home messages from her Plenary session 'PROMS and feedback during trials: a new point at the horizon'.
- [“Today’s trainees will be tomorrow’s leaders”: Why collaboration is critical in paediatric oncology](https://touchoncology.com/insight/todays-trainees-will-be-tomorrows-leaders-why-collaboration-is-critical-in-paediatric-oncology/): Among the emerging voices at the 7th SIOP Europe Annual Meeting, was Dr Miguel Vieira-Martins, (Princess Máxima Center, Utrecht, Netherlands and member of Young SIOPE Steering Committee). He is deeply engaged in both the scientific and collaborative structures driving the field forward. In this interview, he discusses how opportunities in Young SIOPE are supporting early-career professionals, and reflects on the importance of international networks, the rise of immunotherapy and how meetings like SIOPE are accelerating progress from bench to bedside.
- [Uta Dirksen on the power of collaboration in reducing inequalities in childhood cancer](https://touchoncology.com/insight/sp-uta-dirksen-inequalities-childhood-cancer/): At the 7th SIOP Europe Annual Meeting, Professor Uta Dirksen (President, SIOP Europe) outlines a vision for a more equitable and collaborative future in paediatric oncology, one shaped as much by community engagement as by scientific innovation.
- [Advancing early-phase paediatric oncology drug development in Europe](https://touchoncology.com/insight/paediatric-oncology-drug-europe/): At SIOPE 2026, discussions around early phase clinical development highlighted both the scientific advances and structural challenges shaping modern paediatric oncology. Prof Cornelis Van Tilburg is closely involved in both areas through his leadership of the clinical trials unit and multiple investigator-initiated studies in paediatric neuro-oncology. In this interview, he discusses the barriers affecting European early phase research, evolving paediatric trial methodologies, and the importance of international collaboration in precision oncology.
- [Sydney Stern on advancing treatment and advocacy in TGCT](https://touchoncology.com/insight/sp-sydney-stern-tgct/): The impact on patients diagnosed with tenosynovial giant cell tumour (TGCT) can be profound. It is characterized by high recurrence rates, chronic symptoms, and frequent delays in specialist care. Although it is a benign tumor, diffuse TGCT often requires complex multidisciplinary management similar to that used in sarcoma care. In this interview, Dr Sydney Stern (Head of TGCT Support Programs) discusses the evolving treatment landscape, the promise of targeted therapies, and the role of patient advocacy in improving outcomes for people living with this rare tumour.
- [The latest in nuclear oncology: Highlights from EANM’25](https://touchoncology.com/insight/sp-the-latest-in-nuclear-oncology-highlights-from-eanm25/): The 38th Annual Congress of the European Association of Nuclear Medicine (EANM) in Barcelona brought together over 9,400 participants, marking a major milestone. The meeting highlighted major advances in oncologic imaging and theranostics, with a strong emphasis on precision medicine and combination treatment strategies. Across plenary sessions, debates, and late-breaking discussions, the meeting underscored how nuclear medicine is increasingly central to cancer diagnosis, treatment selection, and therapeutic delivery.
- [Reversing VEGF TKI resistance in ccRCC: Early data from the FIT-001 trial](https://touchoncology.com/insight/reversing-vegf-tki-resistance-in-ccrcc-early-data-from-the-fit-001-trial/): New clinical data presented at the 2026 International Kidney Cancer Symposium (IKCS) Europe supports the potential of next-generation FTI darlifarnib, alone and in combination with cabozantinib, to overcome resistance and resensitize tumors to VEGFR TKI therapy in clear cell renal cell carcinoma (ccRCC)
- [AACR 2026 Plenary Session: Rising early-onset cancers take centre stage](https://touchoncology.com/insight/aacr-2026-plenary-session-rising-early-onset-cancers-take-centre-stage/): The plenary session at the AACR Annual Meeting 2026 brought sharp focus to one of oncology’s most urgent challenges: the global rise in early-onset cancers. Across four complementary presentations, speakers combined epidemiology, molecular biology and clinical insight to frame a multifactorial, and still evolving, picture of risk in younger populations. Below, we have broken down the key points and take-home messages from the session.
- [Meet the touchONCOLOGY Future Leaders 2026](https://touchoncology.com/insight/meet-the-touchoncology-future-leaders-2026/): See who the oncology community selected as the rising stars of 2026!
- [Dr Margaret Wheless on empathy, guidance and the rewards of academic oncology: touchONCOLOGY Future Leaders 2026](https://touchoncology.com/insight/fl-dr-margaret-wheless-touchoncology-2026/): In this Future Leaders interview, Margaret Wheless reflects on the mentors who shaped her career, the fulfillment she finds in patient care and teaching, and the importance of empathy, collaboration, and intentional mentorship for emerging oncologists.
- [Dr Juan Gómez Rivas on credibility, mentorship and building a meaningful surgical career: touchONCOLOGY Future Leaders 2026](https://touchoncology.com/insight/fl-dr-juan-gomez-rivas-touchoncology-2026/): In this Future Leaders interview, Dr Gómez Rivas discusses the mentors who shaped his career, the values that sustain a life in surgery and research, and the importance of mentorship, teamwork and resilience for the next generation of urologists.
- [Dr Federico Monaca on shaping a career in modern oncology: touchONCOLOGY Future Leaders 2026](https://touchoncology.com/insight/fl-federico-monaca-touchoncology-2026/): As part of our touchONCOLOGY Future Leaders 2026 programme, Dr Federico Monaca reflects on the mentors who shaped his approach to research and clinical trials, the importance of patience and patient-centred care, and the transformative potential of next-generation immunotherapies.
- [Dr Kevin Keane on global training, collaboration and cancer care across continents: touchONCOLOGY Future Leaders 2026](https://touchoncology.com/insight/fl-kevin-keane-touchoncology-2026/): In this Future Leaders interview, Dr Kevin Keane discusses the mentors who shaped his approach to clinically meaningful research, the integration of surgery and innovation in uro-oncology and the collaborative, patient-centred advances set to transform bladder cancer care.
- [Dr Gabriel Lenz on equity, access and the real-world impact of oncology research: touchONCOLOGY Future Leaders 2026](https://touchoncology.com/insight/fl-dr-gabriel-lenz-touchoncology-2026/): In this touchONCOLOGY Future Leaders 2026 interview, Dr Lenz reflects on the mentorship that shaped his commitment to oncology, the role of research in exposing inequities in cancer care, and why ensuring equitable access to innovation will define the future of the field.
- [Dr Darren Haywood on bridging research and lived experience to improve psychosocial cancer care: touchONCOLOGY Future Leaders 2026](https://touchoncology.com/insight/fl-darren-haywood-psychosocial-cancer-care/): In this Future Leaders interview, Dr Haywood discusses the mentors who shaped her career, the value of combining clinical care with research, and why collaboration and mentorship are essential for the next generation of oncologists.
- [Dr Bishal Gyawali on curiosity, communication and global oncology: touchONCOLOGY Future Leaders 2026](https://touchoncology.com/insight/fl-dr-bishal-gyawali-touchoncology-2026/): In this Future Leaders interview, Dr Gyawali discusses how patient-centered care, evidence-based practice and mentorship have shaped his career, and why curiosity, resilience and purpose are essential for the next generation of oncologists.
- [Dr Soniya Dulal on global collaboration and transforming oncology care in Nepal: touchONCOLOGY Future Leaders 2026](https://touchoncology.com/insight/fl-soniya-dulal-touchoncology-2026/): In this Future Leaders interview, Dr Soniya Dulal discusses the global mentors who shaped her career, the importance of building sustainable oncology systems in Nepal and how precision medicine, palliative care and international collaboration can improve patient outcomes in resource-limited settings.
- [Dr Daniela Di Carlo on aligning personal values with patient-centered care: touchONCOLOGY Future Leaders 2026](https://touchoncology.com/insight/fl-dr-daniela-di-carlo-touchoncology-2026/): In this Future Leaders interview, Dr Di Carlo reflects on the mentors who shaped her career, the lessons of resilience and authenticity she carries forward, and the importance of aligning personal values with patient-centered care and lifelong learning in oncology.
- [Dr Rahat Ul Ain on the value of mentorship, persistence and striving for excellence: touchONCOLOGY Future Leaders 2026](https://touchoncology.com/insight/fl-rahat-ul-ain-touchoncology-2026/): We are delighted to announce Dr Rahat Ul Ain as a touchONCOLOGY Future Leader 2026, selected as a rising star poised to shape the future of CNS tumors, Hodgkin lymphoma and immunodeficiency-associated cancers.
- [Dr Elisa Agostinetto on mentorship, diversity and shaping breast cancer care: touchONCOLOGY Future Leaders 2026](https://touchoncology.com/insight/fl-elisa-agostinetto-touchoncology-2026/): In this Future Leaders interview, Dr Agostinetto discusses the mentors who shaped her career, the value of combining clinical care with research, and why collaboration and mentorship are essential for the next generation of oncologists.

## Learning Zone
- [Potential for Early Intervention in 1L HR+/HER2– Advanced Breast Cancer](https://touchoncology.com/breast-cancer/learning-zone/potential-for-early-intervention-in-1l-hr-her2-advanced-breast-cancer/): Join Dr Seth Wander as he discusses early intervention for HR+/HER2– advanced breast cancer and detection of emerging ESR1 mutations
- [Enhancing personalized care in HR+ early breast cancer: How MGAs help to individualize risk-based systemic treatment decisions](https://touchoncology.com/breast-cancer/learning-zone/enhancing-personalized-care-in-hr-early-breast-cancer-how-mgas-help-to-individualize-risk-based-systemic-treatment-decisions/): Watch leading experts discuss prognostic and predictive factors of HR+ early breast cancer and personalized treatment approaches.
- [IG Tester](https://touchoncology.com/breast-cancer/learning-zone/ig-tester/)
- [CLL Essentials: Diagnosis, Informed Treatment Decisions and Risk Management](https://touchoncology.com/leukemia/learning-zone/cll-essentials-diagnosis-informed-treatment-decisions-and-risk-management/): These infographics review CLL management, from initial diagnosis and staging through treatment initiation and discontinuation, and assessment of patient risks.
- [BTK Inhibitors in CLL: Mechanisms and Management](https://touchoncology.com/leukemia/learning-zone/btk-inhibitors-in-cll-mechanisms-and-management/): This activity explores BTK inhibitors in CLL: how they work, when to start and stop, and safe, effective use.
- [HR+, HER2- Early Breast Cancer: Patient Case](https://touchoncology.com/breast-cancer/learning-zone/hr-her2-early-breast-cancer-patient-case/): This interactive patient case simulation is designed to support risk stratification and treatment decision-making in HR+, HER2− early breast cancer (EBC).
- [High-Risk HR+, HER2− Early Breast Cancer: Risk of Recurrence, Trial Endpoints, and AE Management](https://touchoncology.com/breast-cancer/learning-zone/high-risk-hr-her2%e2%88%92-early-breast-cancer-risk-of-recurrence-trial-endpoints-and-ae-management/): This activity consolidates three educational infographics examining recurrence risk assessment, adjuvant CDK4/6 inhibitor clinical trial data, and adverse event management in patients with high-risk HR+, HER2− early breast cancer (EBC).
- [High-Risk HR+, HER2− Early Breast Cancer: Risk Stratification, Adjuvant CDK4/6 Inhibitors, and Long-Term Outcomes](https://touchoncology.com/breast-cancer/learning-zone/high-risk-hr-her2%e2%88%92-early-breast-cancer-risk-stratification-adjuvant-cdk4-6-inhibitors-and-long-term-outcomes/): This activity brings together expert-led video discussions focused on the identification and management of patients with high-risk HR+, HER2− early breast cancer (EBC).
- [Harnessing CAR-T cell therapy to improve outcomes in RRMM](https://touchoncology.com/multiple-myeloma/learning-zone/harnessing-car-t-cell-therapy-to-improve-outcomes-in-rrmm/): Experts highlight the remaining unmet need in RRMM and how treatment with CAR-T cell therapy may improve patient outcomes.
- [Managing breast cancer with CDK 4/6 inhibition: the long-term efficacy and safety of abemaciclib](https://touchoncology.com/breast-cancer/learning-zone/managing-breast-cancer-with-cdk-4-6-inhibition-the-long-term-efficacy-and-safety-of-abemaciclib/): Join leading oncologists as they discuss the latest long-term data from pivotal trials with abemaciclib plus endocrine therapy, in patients with HR+, HER2-, node-positive, high-risk early breast cancer.
- [Oncogenic mutations in the RAS gene can drive cancer initiation and progression](https://touchoncology.com/colorectal-cancer/learning-zone/oncogenic-mutations-in-the-ras-gene-can-drive-cancer-initiation-and-progression/): Learn how RAS proteins play a crucial role in the regulation of cell proliferation and survival in normal cells. Oncogenic mutations in the RAS gene can drive cancer initiation and progression through disruption of this regulatory balance.
- [Individualizing first-line treatment in advanced bladder cancer: fine-tuning patient care](https://touchoncology.com/bladder-cancer/learning-zone/individualizing-first-line-treatment-in-advanced-bladder-cancer-fine-tuning-patient-care/): Dr Alison Birtle, Dr Enrique Grande, Dr Joana Marinho, Dr Niklas Klümper, Dr David J. Benjamin
- [Overcoming barriers to CAR T-cell therapy referral](https://touchoncology.com/hematologic-malignancies/learning-zone/overcoming-barriers-to-car-t-cell-therapy-referral/): Expert recommendations on referral practices for CAR T-cell therapy eligibility compared with standard of care.
- [Evolving Treatment Strategies in Resectable NSCLC: Insights from CheckMate 816 and CheckMate 77T](https://touchoncology.com/lung-cancer/learning-zone/evolving-treatment-strategies-in-resectable-nsclc-insights-from-checkmate-816-and-checkmate-77t/): Watch in two short videos, leading thoracic oncologists share 2025 data on CheckMate 816 and CheckMate 77T.
- [EBC recurrence risk: Definitions and disease characteristics](https://touchoncology.com/breast-cancer/learning-zone/ebc_recurrence_risk_definitions_and_disease_characteristics/): Watch focused presentations from Dr Tal Sella and Dr Alessandra Morelle, as they explore the latest clinical and real-world data on CDK4/6 inhibitors in HR+ HER2- early breast cancer (EBC).
- [The impact of Isa-VRd on newly-diagnosed multiple myeloma: implications for standard of care treatment](https://touchoncology.com/multiple-myeloma/learning-zone/the-impact-of-isa-vrd-on-newly-diagnosed-multiple-myeloma-implications-for-standard-of-care-treatment/): Understand the efficacy of Isa-VRd on MRD status, quality of life and long-term PFS in newly-diagnosed multiple myeloma.
- [Finding the target in METex14 skipping NSCLC – optimizing patient benefit through best practice](https://touchoncology.com/lung-cancer/learning-zone/finding-the-target-in-metex14-skipping-nsclc-optimizing-patient-benefit-through-best-practice/): In this activity, watch leading oncology experts discuss recent consensus statements from near-global groups on the diagnosis, testing, and management of METex14 skipping NSCLC.
- [Tools to guide treatment decisions in early breast cancer: Genomic testing and emerging role of MRD](https://touchoncology.com/breast-cancer/learning-zone/tools-to-guide-treatment-decisions-in-early-breast-cancer-genomic-testing-and-emerging-role-of-mrd/): Watch leading oncology experts discuss the clinical impact of genomic assays in early breast cancer and explore the future potential of molecular residual disease (MRD) testing.
- [The role of fibroblast growth factor receptor (FGFR) alterations in advanced urothelial carcinoma](https://touchoncology.com/bladder-cancer/learning-zone/role-of-fibroblast-growth-factor-receptor-alterations-in-advanced-urothelial-carcinoma/): Watch to learn more about FGFR alterations and how a consensus on molecular classification impacts our understanding of muscle-invasive bladder cancer.1,2
- [Improving outcomes in acute lymphoblastic leukaemia](https://touchoncology.com/leukemia/learning-zone/trt-improving-outcomes-in-all/): Dr Nicola Gökbuget, Prof. Carmelo Rizzari, Prof. Stephen Hunger
- [Efficacy and safety results from the Phase 3 NETTER-1 trial with LUTATHERA® (lutetium (177Lu) oxodotreotide)](https://touchoncology.com/gastrointestinal-cancers/learning-zone/netter-1-a-phase-3-clinical-trial-in-patients-with-midgut-neuroendocrine-tumours-net/): Discover key efficacy and safety results from an international Phase 3 clinical trial of LUTATHERA® in patients with midgut neuroendocrine tumours (NET).1
- [Clinical decision making in advanced ovarian and advanced/recurrent endometrial cancers](https://touchoncology.com/gynecologic-cancers/learning-zone/trt-adv-oc-adv-recur-ec/): Prof. Jalid Sehouli, Prof. Nicole Concin, Prof. Shibani Nicum, Ms Lynn Buckley

## Journal Editions
- [touchREVIEWS in Oncology & Haematology – Volume 22, Issue 1 – 2026](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/touchreviews-in-oncology-haematology-volume-22-issue-1-2026/): We are pleased to present the latest issue of touchREVIEWS in Oncology & Haematology, which brings together a diverse collection of articles reflecting the growing complexity of modern cancer care and the continued evolution of precision medicine. Across tumour types, this edition explores emerging targeted therapies, treatment-related challenges and novel biological insights, while also highlighting the significant unmet needs that remain in oncology.
- [touchREVIEWS in Oncology & Haematology – Volume 21, Issue 2 – 2025](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/touchreviews-in-oncology-haematology-volume-21-issue-2-2025/): We are pleased to present the latest edition of touchREVIEWS in Oncology & Haematology, featuring cutting-edge insights across cancer care. This issue explores evolving therapies for advanced hepatocellular carcinoma, the role of gut microbiota in cancer immunotherapy, and new approaches in cervical cancer management. In haematology, we review advances in treating thrombotic thrombocytopenic purpura and spotlight early-onset lung cancer’s unique challenges. Together, these articles highlight innovation, collaboration, and the ongoing pursuit of improved outcomes in oncology and haematology.
- [touchREVIEWS in Oncology & Haematology – Volume 21, Issue 1 – 2025](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/touchreviews-in-oncology-haematology-volume-21-issue-1-2025/): Welcome to Volume 21, Issue 1 of touchREVIEWS in Oncology & Haematology. This issue brings together a selection of expert perspectives and reviews that reflect the dynamic developments across the oncology and haematology landscape. Topics include advancements in lymphoma management, innovative diagnostic strategies in melanoma, updates on treatment approaches for biliary tract and lung cancers, and evolving therapies in leukaemia and head and neck malignancies.
- [touchREVIEWS in Oncology & Haematology – Volume 20, Issue 2 – 2024](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/touchreviews-in-oncology-haematology-volume-20-issue-2-2024/): Welcome to Volume 20, Issue 2 of touchREVIEWS in Oncology & Haematology. This edition delves into key advancements and challenges in oncology, featuring insightful articles on a diverse range of topics, including breast, colorectal, gastrointestinal, lung and prostate cancers. We hope this issue inspires meaningful discussion and informs your practice with the latest evidence and expert perspectives.
- [touchREVIEWS in Oncology & Haematology – Volume 20, Issue 1 – 2024](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/touchreviews-in-oncology-haematology-volume-20-issue-1-2024/): Welcome to the latest edition of touchREVIEWS in Oncology & Haematology! This issue features some of the recent key developments in oncological and haematological disease, including editorials, review articles and original research exploring the latest in breast cancer, endometrial cancer, gastrointestinal cancer, leukemia, lung cancer and dermatological cancers.
- [touchREVIEWS in Oncology & Haematology – Volume 19, Issue 2 – 2023](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/touchreviews-in-oncology-haematology-volume-19-issue-2-2023/): Welcome to the latest edition of touchREVIEWS in Oncology & Haematology! This issue features some of the recent key developments in oncological and haematological disease, including editorials, review articles and original research exploring the latest in paediatric oncology, neuro-oncology, breast cancer, gastrointestinal cancer, sickle cell disease and β-thalassaemia.
- [touchREVIEWS in Oncology & Haematology – Volume 19, Issue 1 – 2023](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/touchreviews-in-oncology-haematology-volume-19-issue-1-2023/): Welcome to the latest edition of touchREVIEWS in Oncology & Haematology! This issue features some of the recent key developments in oncological and haematological disease, including expert interviews, editorials and review articles exploring the latest in lung cancer, paediatric oncology, breast cancer, colorectal cancer, esophageal squamous cell carcinoma, biliary tract cancer, urothelial carcinoma, squamous cell anal carcinoma, cold agglutinin disease and multiple myeloma.
- [touchREVIEWS in Oncology & Haematology – Volume 18, Issue 2 – 2022](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/touchreviews-in-oncology-haematology-volume-18-issue-2-2022/): Welcome to the latest edition of touchREVIEWS in Oncology & Haematology. This issue opens with an editorial looking at the ATLAS trial and how this might shape the future of post-transplant maintenance therapy for patients with multiple myeloma. The journal then showcases a series of review articles spanning a wide range of important topics including breast cancer, colorectal cancer, diagnostics in oesophageal and oesophagastric junction cancers bladder cancer, prostate cancer, head and neck cancer, leukaemia and supportive cancer care.
- [touchREVIEWS in Oncology & Haematology – Volume 18, Issue 1 – 2022](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/touchreviews-in-oncology-haematology-volume-18-issue-1-2022/): Welcome to the latest edition of touchREVIEWS in Oncology & Haematology. This issue features a series of review articles exploring the latest advances in many areas of both oncology and haematology, including the risk of thrombotic complications among patients with COVID-19, pembrolizumab and chemotherapy in cervical cancer, targeted therapy in both gastrointestinal oncology and neuroendocrine tumours, immunotherapy in sarcoma, BTK inhibitors in lymphoma, a summary of the major studies at ASH 2021 and much more!
- [touchREVIEWS in Oncology & Haematology – Volume 17, Issue 2 – 2021](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/touchreviews-in-oncology-haematology-volume-17-issue-2/): Welcome to the latest edition of touchREVIEWS in Oncology & Haematology!
- [touchREVIEWS in Oncology & Haematology – VOLUME 17 ISSUE 1 – 2021](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/touchreviews-in-oncology-haematology-volume-17-issue-1-2021/): Welcome to the inaugral issue of touchREVIEWS in Oncology & Haematology (formerly Oncology & Hematology Review ), which aims to summarize the latest clinical data and provide practical advice to help busy physicians in their daily practice. The decision to change the title of the journal has been taken after a great year for touchONCOLOGY, and we feel that in an increasingly global research community, submissions were being limited by an assumed primary reach to one regional audience. Together with the recent closure of European Oncology & Haematology, this will allow the journal to grow, while reflecting the new international audience in the change of title.
- [ONCOLOGY & HEMATOLOGY (US) – VOLUME 16 ISSUE 2 – FALL 2020](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/oncology-hematology-us-volume-16-issue-2-fall-2020/)
- [EUROPEAN ONCOLOGY & HAEMATOLOGY – VOLUME 16 – ISSUE 1 – SUMMER 2020](https://touchoncology.com/journals/european-oncology-haematology/european-oncology-haematology-volume-16-issue-1-summer-2020/)
- [ONCOLOGY & HEMATOLOGY (US) – VOLUME 16 ISSUE 1 – SPRING 2020](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/oncology-hematology-us-volume-16-issue-1-spring-2020/)
- [EUROPEAN ONCOLOGY & HAEMATOLOGY – VOLUME 15 – ISSUE 2 – WINTER 2019](https://touchoncology.com/journals/european-oncology-haematology/european-oncology-haematology-volume-15-issue-2-winter-2019/)
- [ONCOLOGY & HEMATOLOGY (US) – VOLUME 15 ISSUE 2 – FALL 2019](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/oncology-hematology-us-volume-15-issue-2-fall-2019/)
- [EUROPEAN ONCOLOGY & HAEMATOLOGY – VOLUME 15 – ISSUE 1 – SUMMER 2019](https://touchoncology.com/journals/european-oncology-haematology/european-oncology-haematology-volume-15-issue-1-summer-2019/)
- [ONCOLOGY & HEMATOLOGY REVIEW – VOLUME 15 – ISSUE 1 – SPRING 2019](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/oncology-hematology-review-volume-15-issue-1-spring-2019/)
- [EUROPEAN ONCOLOGICAL DISEASE – VOLUME 2 ISSUE 2 – WINTER 2006](https://touchoncology.com/journals/european-oncology-haematology/european-oncological-disease-volume-2-issue-2-winter-2006/)
- [EUROPEAN ONCOLOGICAL DISEASE – VOLUME 3 ISSUE 1 – SUMMER 2007](https://touchoncology.com/journals/european-oncology-haematology/european-oncological-disease-volume-3-issue-1-summer-2007/)
- [EUROPEAN ONCOLOGICAL DISEASE – VOLUME 2 ISSUE 1- SUMMER 2006](https://touchoncology.com/journals/european-oncology-haematology/european-oncological-disease-volume-2-issue-1-summer-2006/)
- [EUROPEAN HAEMATOLOGY REVIEW – VOLUME 1 – SUMMER 2007](https://touchoncology.com/journals/european-oncology-haematology/european-haematology-review-volume-1-summer-2007/)
- [EUROPEAN ONCOLOGICAL DISEASE – VOLUME 3 ISSUE 2 – WINTER 2007](https://touchoncology.com/journals/european-oncology-haematology/european-oncological-disease-volume-3-issue-2-winter-2007/)
- [EUROPEAN ONCOLOGY REVIEW – VOLUME 1 – SUMMER 2005](https://touchoncology.com/journals/european-oncology-haematology/european-oncology-review-volume-1-summer-2005/)
- [EUROPEAN ONCOLOGY – VOLUME 4 ISSUE 1 – SUMMER 2008](https://touchoncology.com/journals/european-oncology-haematology/european-oncology-volume-4-issue-1-summer-2008/)
- [EUROPEAN HAEMATOLOGY – VOLUME 2 – SUMMER 2008](https://touchoncology.com/journals/european-oncology-haematology/european-haematology-volume-2-summer-2008/)
- [EUROPEAN ONCOLOGY – VOLUME 4 ISSUE 2 – WINTER 2008](https://touchoncology.com/journals/european-oncology-haematology/european-oncology-volume-4-issue-2-winter-2008/)
- [EUROPEAN ONCOLOGY – VOLUME 5 – SUMMER 2009](https://touchoncology.com/journals/european-oncology-haematology/european-oncology-volume-5-summer-2009/)
- [EUROPEAN HAEMATOLOGY – VOLUME 3 – SUMMER 2009](https://touchoncology.com/journals/european-oncology-haematology/european-haematology-volume-3-summer-2009/)
- [EUROPEAN HAEMATOLOGY – VOLUME 4 – SUMMER 2009](https://touchoncology.com/journals/european-oncology-haematology/european-haematology-volume-4-summer-2009/)
- [EUROPEAN ONCOLOGY – VOLUME 6 ISSUE 1 – SUMMER 2010](https://touchoncology.com/journals/european-oncology-haematology/european-oncology-volume-6-issue-1-summer-2010/)
- [EUROPEAN ONCOLOGY – VOLUME 6 ISSUE 2 – WINTER 2010](https://touchoncology.com/journals/european-oncology-haematology/european-oncology-volume-6-issue-2-winter-2010/)
- [EUROPEAN ONCOLOGY & HAEMATOLOGY – VOLUME 7 ISSUE 1 – SPRING 2011](https://touchoncology.com/journals/european-oncology-haematology/european-oncology-haematology-volume-7-issue-1-spring-2011/)
- [EUROPEAN ONCOLOGY & HAEMATOLOGY – VOLUME 7 ISSUE 2 – SUMMER 2011](https://touchoncology.com/journals/european-oncology-haematology/european-oncology-haematology-volume-7-issue-2-summer-2011/)
- [ONCOLOGY & HEMATOLOGY REVIEW – VOLUME 14 – ISSUE 2 – FALL 2018](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/oncology-hematology-review-volume-14-issue-2-fall-2018/)
- [ONCOLOGY & HEMATOLOGY REVIEW – VOLUME 14 – ISSUE 1 – SPRING 2018](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/oncology-hematology-review-volume-14-issue-1-spring-2018/)
- [ONCOLOGY & HEMATOLOGY – REVIEW VOLUME 13 ISSUE 2 – FALL 2017](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/oncology-hematology-review-volume-13-issue-2-fall-2017/)
- [ONCOLOGY & HEMATOLOGY – REVIEW VOLUME 13 ISSUE 1 – SPRING 2017](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/oncology-hematology-review-volume-13-issue-1-spring-2017/)
- [EUROPEAN ONCOLOGY & HAEMATOLOGY – VOLUME 7 ISSUE 3 – AUTUMN 2011](https://touchoncology.com/journals/european-oncology-haematology/european-oncology-haematology-volume-7-issue-3-autumn-2011/)
- [ONCOLOGY & HEMATOLOGY – REVIEW VOLUME 12 ISSUE 2 – FALL 2016](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/oncology-hematology-review-volume-12-issue-2-fall-2016/)
- [ONCOLOGY & HEMATOLOGY – REVIEW VOLUME 12 ISSUE 1 – SPRING 2016](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/oncology-hematology-review-volume-12-issue-1-spring-2016/)
- [ONCOLOGY & HEMATOLOGY – REVIEW VOLUME 11 ISSUE – 2 FALL 2015](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/oncology-hematology-review-volume-11-issue-2-fall-2015/)
- [EUROPEAN ONCOLOGY & HAEMATOLOGY – VOLUME 7 ISSUE 4 – WINTER 2011](https://touchoncology.com/journals/european-oncology-haematology/european-oncology-haematology-volume-7-issue-4-winter-2011/)
- [ONCOLOGY & HEMATOLOGY (US) – VOLUME 11 ISSUE 1 – SPRING 2015](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/https-www-touchoncology-com-journals-editions-oncology-hematology-us-volume-11-issue-1-spring-2015/)
- [ONCOLOGY & HEMATOLOGY (US) – VOLUME 10 ISSUE 2 – FALL 2014](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/oncology-hematology-us-volume-10-issue-2-fall-2014/)
- [ONCOLOGY & HEMATOLOGY (US) – VOLUME 10 ISSUE 1 – SPRING 2014](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/oncology-hematology-us-volume-10-issue-1-spring-2014/)
- [ONCOLOGY & HEMATOLOGY REVIEW (US) – VOLUME 9 ISSUE 2 – FALL 2013](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/oncology-hematology-review-us-volume-9-issue-2-fall-2013/)
- [ONCOLOGY & HEMATOLOGY REVIEW (US) – VOLUME 9 ISSUE 1 – SPRING 2013](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/oncology-hematology-review-us-volume-9-issue-1-spring-2013/)
- [ONCOLOGY & HEMATOLOGY REVIEW (US) – VOLUME 8 ISSUE 2 – FALL 2012](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/oncology-hematology-review-us-volume-8-issue-2-fall-2012/)
- [ONCOLOGY & HEMATOLOGY REVIEW (US) – VOLUME 8 ISSUE 1 – SPRING 2012](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/oncology-hematology-review-us-volume-8-issue-1-spring-2012/)

## Editorial Board
- [Axel Merseburger](https://touchoncology.com/editorial-board/axel-s-merseburger/): Prof. Dr. med. Axel Stuart Merseburger is a highly experienced urologist with over 21 years of practice. He works at the Department of Urology at the University Hospital Schleswig-Holstein in Lubeck, Germany and specializes in urology and robotic surgery. Dr Merseburger is considered an expert in his field with a wide range of qualifications and achievements. Having studied medicine at top institutions such as the Hannover Medical School and the Harvard Medical School, Dr Merseburger has gained extensive knowledge and expertise. He has completed various fellowships and training, including a scholarship at the Uniformed Services University in Washington and a fellowship at the Henry M Jackson Foundation Center for Prostate Disease Research. Dr Merseburger has published 442 scientific publications, demonstrating his dedication to research and innovation. He has received numerous awards and prizes, including the Werner Staehler Memorial and Urologia Internationalis prizes. With his wealth of experience and expertise, Dr Merseburger is known for his contributions to the field of urology. He is highly regarded for his skills in robotic surgery and his focus on prostate cancer. His dedication to improving patient outcomes and advancing the field of urology makes him a highly respected and trusted doctor. Overall, Prof. Dr. med. Axel Stuart Merseburger is an accomplished urologist who brings knowledge and expertise to his practice. His dedication to research, innovative treatments and patient care makes him a valuable asset to the medical community.
- [Sara M Tolaney](https://touchoncology.com/editorial-board/sara-m-tolaney/): Dr. Tolaney is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy. She is a member of the National Cancer Institute Breast Cancer Steering Committee and is Vice Chair for Late-Stage Development in Breast Cancer in the Alliance for Clinical Trials in Oncology. Her research has been funded by the Breast Cancer Research Foundation and Susan G. Komen.  She currently chairs multiple phase 3 trials in breast cancer and serves on several steering committees for practice-changing trials.  Her work has been published in journals such as the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, and others.  She received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007.
- [Domenica Lorusso](https://touchoncology.com/editorial-board/domenica-lorusso/): Domenica Lorusso, MD, PhD, is Director of Gynaecological Oncology Unit at Humanitas Hospital San Pio X, Milan, and Full Professor of Obstetrics and Gynaecology, Humanitas University, Rozzano, Milan. Prof. Lorusso has been involved in gynecological oncology research for more than 25 years and has conducted or participated in approximately 250 phase I-IV clinical trials in gynecological malignancies. At present she is Principal Investigators of more than 60 studies.
- [Matti S Aapro](https://touchoncology.com/editorial-board/matti-s-aapro/): Dr Aapro coordinates the Sharing Progress in Cancer Care (SPCC) program of the European School of Oncology (ESO) and serves the International Society for Geriatric Oncology (SIOG) as an Executive Board member. He has been a member of the board of the European Organization for Research and Treatment of Cancer (EORTC) and of the European Society of Medical Oncology (ESMO). He is Past President of the Multinational Association for Supportive Care in Cancer (MASCC), and is now on its Board of Directors for 2012 to 2014.
- [Paolo A Ascierto](https://touchoncology.com/editorial-board/paolo-a-ascierto/): Paolo A. Ascierto obtained his medical degree from the University of Naples, Italy, the institution where he subsequently earned his Board Certification in Oncology. He went on to serve consecutive positions at the National Tumor Institute “Fondazione G. Pascale”, in Naples, as a postdoctoral fellow and then as Vice Director of the Department of Clinical Immunology. Professor Ascierto is currently Director of the Unit of Melanoma, Cancer Immunotherapy and Innovative therapy at that same institution. He is an active Scientific Reviewer for several international journals, including, JCO, Lancet Oncology, and Clinical Cancer Research, as well as being the Editor-in-Chief of the Combination Strategies section of the Journal of Translational Medicine and Chief Section Editor of Expert Reviews of Immunology Vaccines and Informatics. As a result of Professor Ascierto’s experience and expertise, he has been a valued invited speaker at more than 350 national and international meetings. Furthermore, he is an active member of the Italian Society of Medical Oncology (AIOM), American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), European Organization for Research and Treatment of Cancer (EORTC) and Society of Immuno Therapy of Cancer (SITC). Professor Ascierto has presided as Principal Investigator on over 50 clinical trials and he is the author of numerous publications in peer-reviewed journals. Such journals include: The New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, and Clinical Cancer Research among others. Primarily, his major research interests are the genetics and proteomics of melanoma, the assessment of molecular markers for tumour progression in melanoma, management of targeted therapies for melanoma, vaccination treatments and immunotherapy of cancer, biochemical and immunological monitoring, and combination approaches for the cancer treatment.
- [Maurice Pérol](https://touchoncology.com/editorial-board/maurice-perol/): Maurice Pérol, M.D., was Associate Professor of Pneumology and Head of the Department of Thoracic Oncology at the Croix-Rousse University Hospital in Lyon, France from 1993 until 2011. He joined in 2011 the Medical Oncology Department of Léon Bérard Cancer Center in Lyon, in which he is responsible for Thoracic Oncology. His fields of scientific work include clinical phase I, II and III studies in lung cancer, especially in advanced non-small cell lung cancer; this work involves being a principal investigator or key investigator in several French or international cooperative studies. Of note, he was the principal investigator of the IFCT-GFPC 0502 maintenance French study which involves more than 70 centers in France and the co-principal investigator of the international REVEL phase III study assessing ramucirumab in second-line treatment of NSCLC. He is an active member of many scientific societies, including ASCO, IASLC and ESMO, and collaborative groups. He was the Chairman of the Groupe Français de Pneumo-Cancérologie (GFPC) from 1998 to 2002 and Executive Board member of the French Cooperative Group of Thoracic Oncology "Intergroupe Francophone de Cancérologie Thoracique" (IFCT) from 1999 to 2003; he is member of the IFCT Scientific Board since 2003. He is the author or co-author of more than 140 publications in peer-reviewed journals.
- [Michael K Gibson](https://touchoncology.com/editorial-board/michael-k-gibson-md/): Michael K Gibson, MD, PhD FACP, is Director of Translational Research for Esophago-Gastric Cancer (EGC) at the Vanderbilt-Ingram Cancer Center (VICC), where he also holds a faculty position as Professor of Medicine.
- [Jorge Cortes](https://touchoncology.com/editorial-board/jorge-cortes/): Director, Georgia Cancer Center, Augusta University, Augusta, GA, USA
- [Benjamin A Weinberg](https://touchoncology.com/editorial-board/benjamin-a-weinberg/): Dr. Weinberg is an Associate Professor of Medicine, Division of Hematology and Oncology, in the Lombardi Comprehensive Cancer Center (LCCC) at Georgetown University, specializing in gastrointestinal oncology and sarcoma. A native of Bethesda, Maryland, he graduated from Sidwell Friends School in northwest Washington. He received his undergraduate degree in biomedical science at the University of Pennsylvania and his medical degree at the Keck School of Medicine of the University of Southern California. He went on to complete his post-graduate medical training with a residency in internal medicine and fellowship in hematology and oncology at MedStar Georgetown University Hospital. Dr. Weinberg is interested in developing new therapies for colorectal and pancreatic cancers by translating research from animal models into early phase clinical trials in humans.
- [Erik Aerts](https://touchoncology.com/editorial-board/erik-aerts/): Erik is President of the Haematology Nurses & Healthcare Professionals Group.
- [Pinkal Desai](https://touchoncology.com/editorial-board/pinkal-desai/): Pinkal Desai MD, MPH is an Assistant Professor of Medicine at Weill Cornell Medical College and Assistant Attending Physician at the New York-Presbyterian Hospital.
- [John Mascarenhas](https://touchoncology.com/editorial-board/john-mascarenhas/): Dr John Mascarenhas is a Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) and a member of the Tisch Cancer Institute in New York City. Dr Mascarenhas is the Director of Center of Excellence in Blood Cancers and Myeloid Disorders, Director of the Adult Leukemia Program, and Leader of Clinical Research within the Myeloproliferative Disorders Program at Mount Sinai.  As a clinical investigator in malignant hematology with a focus in translational research involving MPNs, he is primarily responsible for the clinical trials portion of the Myeloproliferative Disorders Program at ISMMS. Dr Mascarenhas is also the Principal Investigator (PI) of the clinical trials project within the National Cancer Institute sponsored Myeloproliferative Neoplasms Research Consortium (MPN-RC). He has served as PI or Study Chair of multiple investigator-initiated and industry-sponsored early and late phase clinical trials evaluating innovative approaches to the treatment of MPNs and secondary acute leukemia.
- [Kristen Sanfilippo](https://touchoncology.com/editorial-board/kristen-sanfilippo/): Dr. Kristen Sanfilippo is a Hematologist in the Division of Hematology at Washington University School of Medicine St. Louis and a Staff Physician in the Division of Hematology/Oncology at John Cochran Veterans Administration Medical Center St. Louis, USA. She is a co-chair of the International Society on thrombosis and Haemostasis Scientific and Standardization Committee for Hemostasis and Malignancy.  In addition to clinical training in hematology/oncology, she earned a Masters in Population Health Sciences at Washington University St. Louis School of Medicine in 2012. Since completion of her Master’s degree, Dr. Sanfilippo has focused her research on health outcomes in patients with venous thromboembolism with a focus on cancer-associated thrombosis. Her research group developed and validated a risk prediction model, IMPEDE VTE, to identify patients with multiple myeloma starting chemotherapy at high-risk of venous thromboembolism. In addition, through a collaboration with a research team at University of Washington School of Medicine, they developed the SAVED score to predict risk of venous thromboembolism in multiple myeloma patients receiving an immunomodulatory agent. Both IMPEDE VTE and the SAVED score are recommended as the risk prediction models of choice by the National Comprehensive Cancer Network (NCCN) clinical guidelines. Her clinical and research interests continue to focus on venous thromboembolism and cancer-associated thrombosis with her current work focused on understanding risk-factors for anticoagulant-related bleeding in patients with cancer.
- [Igor Gómez-Randulfe Rodríguez](https://touchoncology.com/editorial-board/igor-gomez-randulfe-rodriguez/): Dr Igor Randulfe is a Consultant in Medical Oncology at The Christie NHS Foundation Trust, specialising in thoracic and acute oncology. He trained in Medical Oncology in Galicia, Spain, before moving to Manchester in 2023 to join The Christie lung cancer team. He is actively involved in clinical trials and real-world research in lung cancer, with particular interests in immunotherapy, small cell lung cancer and EGFR-mutant non small cell lung cancer. He has authored multiple peer reviewed publications and regularly contributes to national and international thoracic oncology meetings.
- [Alexey V Danilov](https://touchoncology.com/editorial-board/alexey-v-danilov/): Dr. Danilov earned his medical degree in Russia and completed a fellowship in hematology/oncology at Tufts Medical Center, in Boston, United States. He is a physician-scientist with background in molecular biology and cancer cell signaling and expertise in oncologic drug development. He leads an independent research program in B-cell malignancies which bridges the understanding of B-cell biology with early clinical evaluation of novel therapeutics.
- [Petros Grivas](https://touchoncology.com/editorial-board/petros-grivas/): Dr. Petros Grivas is a board-certified medical oncologist with expertise and experience in treating genitourinary (GU) cancers. He is the Clinical Director of the Genitourinary Cancers Program at University of Washington and Seattle Cancer Care Alliance. He is an Associate Professor in the Dept. of Medicine, Division of Medical Oncology. He is an Associate Member at the Fred Hutchinson Cancer Research Center. He started on those positions in January 2018. Dr. Grivas completed his training at the University of Patras Medical School and took his M.D. degree in 2005; he then pursued Ph.D. in Medical Oncology under the mentorship of key academic faculty and defended his thesis successfully in late 2008. He completed his Residency in Internal Medicine at Hahnemann University Hospital/Drexel University College of Medicine (Philadelphia, USA) in 2010. He then completed his Fellowship in Hematology/Oncology at University of Michigan (Ann Arbor, USA) in 2013. He stayed there as Clinical Lecturer for another year before he was recruited as Assistant Professor at the Cleveland Clinic (Cleveland, USA), where he was leading the bladder/urothelial cancer program, pursuing clinical and translational research, teaching and mentoring trainees, and seeing patients with GU cancers. He has had a main role in clinical trials that led to the FDA approval of new drugs for bladder/urothelial cancer (e.g. avelumab switch maintenance based on Javelin Bladder100, sacituzumab govitecan based on TROPHY-U-01), and is considered a key opinion, thought leader and international expert, giving lectures in several countries, educating oncologists, other healthcare providers and trainees, leading large innovative clinical trials, reviewing grant proposals and manuscripts, and publishing novel and important research. He is dedicated to efficient, personalized, and outstanding patient care and believes in optimal patient-physician relationship as well as community outreach.
- [Elias Jabbour](https://touchoncology.com/editorial-board/elias-jabbour/): Dr Elias Jabbour graduated from the Saint Joseph’s School of Medicine in 1998 and joined, thereafter, the Hotel Dieu de France University Hospital as a resident. In 2001, he pursued in fellowship in Hematology-Oncology at the Gustave Roussy Institute. In 2003, he joined the University of Texas M. D. Anderson Cancer as a fellow in the Department of Hematology/Leukemia and Stem cell transplantation. Thereafter, in 2007, he joined the faculty in the Leukemia department as Assistant Professor.
- [Tycel Phillips](https://touchoncology.com/editorial-board/tycel-phillips/): Cancer care is a sort of personal mission for Tycel Phillips, M.D.
- [Martin Hutchings](https://touchoncology.com/editorial-board/martin-hutchings/): Dr Hutchings has been the Chairman of the EORTC lymphoma group since 2013 and a faculty member for the EHA Clinical Research Training in Haematology programme.
- [Federico Monaca](https://touchoncology.com/editorial-board/federico-monaca/): Dr Federico Monaca graduated in 2012 from Università Cattolica del Sacro Cuore in Rome and completed his residency at Fondazione Policlinico Universitario A. Gemelli with top honours, earning full marks cum laude. He is currently a Senior Clinical Research Fellow at The Christie NHS Foundation Trust, where he leads clinical and translational research focused on identifying predictive factors of response in extensive-stage small cell lung cancer. A PhD candidate, his research explores the role of cancer stem cells in the neoadjuvant setting. Dr Monaca has authored more than 30 publications and has contributed as a sub-investigator to over 40 clinical trials.
- [Isabelle Ray-Coquard](https://touchoncology.com/editorial-board/isabelle-ray-coquard/): Prof. Ray-Coquard obtained her medical degree in 1997 specializing in oncology. In 2003 she received her PhD from the Université Claude Bernard for her research on the independents factors that determine medical practices in oncology. She also received Master’s degrees in in statistics in 1995 and in medical economy in 1996. From 2008 to 2013, she has served as Chairman of the gynaecologic group for clinical trials of the French National Cancer Institute (INCA) and she is currently the Network Director of the national network dedicated to diagnosis and management of the rare gynecological cancer (www.ovaire-rare.org ), a network funded by the INCA commission. At the Groupe d’investigateurs national evaluation des cancers de l’ovaire (GINECO), she has been active in the translational research advisory committee, the scientific committee, and as a chairman of endometrial cancer subgroup and the rare tumors committee. Since 2002, she is also developing translational research dedicated to ovarian cancer with the INSERM within the CRCL directed by A Puisieux within the CLB campus, and more directly with the research on rare gyn cancer biology (Carcinosarcoma, Granulosa cell tumors). From 2009 to 2018, she was the chairman of the rare cancer working group from GCIG (gynaecological cancer intergroup) dedicated to clinical trials in the field of all rare gynaecological cancers. She is president of the GINECO group since 2019. Member of the ESGO council since 2021 and Chair of the Gynecological track for ESMO since 2021. She is an active member of a number of professional groups, including the American Society of Clinical Oncology, the Connective Tissue Oncology Society, the French Society of Cancer, the European Association of Cancer Research, the EORTC organisation and the European Society for Medical Oncology (ESMO) and the European Society of Gynaecological Oncology (ESGO).
- [Ana Tecic Vuger](https://touchoncology.com/editorial-board/ana-tecic-vuger/): Dr Ana Tecic Vuger is a medical oncologist with a dedicated focus on breast cancer. She graduated from the University of Zagreb School of Medicine and completed her specialty training in medical oncology, earning both ESMO and national board certifications. She also holds a PhD in breast cancer. Dr Tecic Vuger currently works at the University Hospital for Tumors, part of the Sestre milosrdnice University Hospital Center in Zagreb, Croatia, where she has served as acting head of the Breast Cancer Department within the Medical Oncology Division. She is actively involved in international professional organizations, including the European Society for Medical Oncology (ESMO), where she currently serves as a member of the Young Oncologist Committee, and the European School of Oncology (ESO), where she acts as an ESO Ambassador. She has been awarded several international fellowships and mentorships through ESMO, ESO, and ASCO.
- [Toshinari Yamashita](https://touchoncology.com/editorial-board/toshinari-yamashita/): Department of Breast Surgery and Oncology, Kanagawa Cancer Center, Yokohama, Japan
- [Hannah Russon](https://touchoncology.com/editorial-board/hannah-russon/): Hannah is a registered nurse and the current leader of the Velindre Oncology Academy, Cardiff, Wales, UK. With extensive experience in varying roles within oncology and haematology, Hannah has recently shifted her focus to education, initially supporting nursing professionals and now expanding to the broader multi-professional workforce. Hannah also holds a PGCE and a MSc (education for health professional).
- [Bleddyn Edwards](https://touchoncology.com/editorial-board/bleddyn-edwards/): Bleddyn Edwards, based in Lampeter, GB, is currently a Lead Cancer Pharmacist at Hywel Dda University Health Board. Bleddyn Edwards brings experience from previous roles at Hywel Dda University Health Board, Rutherford Healthcare and Hywel Dda Health Board. Bleddyn Edwards holds a 2021 - 2023 Diploma in Oncology at Newcastle University.
- [John L Marshall](https://touchoncology.com/editorial-board/john-l-marshall-md/): John Marshall, MD, is a global leader in the research and development of drugs for colon cancer and other GI cancers. He is the principal investigator of over 150 clinical trials, at the local as well as national levels. Dr Marshall is the clinical director of oncology for Georgetown University Hospital, associate director for clinical care of the Lombardi Comprehensive Cancer Center, and chief of the Division of Hematology-Oncology. He is widely published in the field of clinical oncology, reviews manuscripts for eight journals, and holds peer-reviewed grants from the National Institutes of Health.
- [Ken Kato](https://touchoncology.com/editorial-board/ken-kato/): Dr Ken Kato is a medical oncologist and the Chief of the Department of Head and Neck, Esophageal Medical Oncology, and Gastrointestinal Medical Oncology at the National Cancer Center Hospital, Tokyo, Japan (2020-2024). Additionally, he serves as the Chief of the Biobank Translational Research Support Section within the Clinical Research Coordinating Section at the Clinical Research Support Office of the same hospital. Dr Kato’s primary focus lies in chemotherapy and chemoradiotherapy for esophageal, esophagogastric and gastric cancers. He has been an active contributor to the Japan Esophageal Oncology Group of the JCOG, which is Japan's leading clinical trial group for cancer.
- [Bernd Jilma](https://touchoncology.com/editorial-board/bernd-jilma/): Bernd Jilma, MD, is a Full Professor and Deputy Head of the Department of Clinical Pharmacology at the Medical University of Vienna. His scientific interests encompass coagulation research, anaphylaxis, rare diseases, biologics, and vaccines. Since 2001, Dr. Jilma has been a principal investigator in phase I, II, and III clinical trials, including multinational studies. He has published over 525 peer-reviewed articles in esteemed journals such as NEJM, Lancet, Lancet Infect Dis, JACC, Blood, Circulation, and Am J Respir Crit Care Med.
- [Gabriel Lenz](https://touchoncology.com/editorial-board/gabriel-lenz/): Dr. Gabriel Lenz is a physician graduated from the Pontifical Catholic University of Rio Grande do Sul (PUCRS) in Brazil. He completed clinical training in Brazil and international electives in the United States at institutions including the Sylvester Comprehensive Cancer Center and Moffitt Cancer Center. He has conducted research on disparities in cancer diagnosis and treatment, with a focus on social determinants of health and healthcare system inefficiencies, aiming to improve cancer outcomes for underserved populations. Currently, he is an Internal Medicine resident at AdventHealth in Orlando, Florida, with a strong focus on clinical oncology and research.
- [Esra Gülderen](https://touchoncology.com/editorial-board/esra-gulderen/): Dr Esra Gülderen is a Resident physician at Uludağ University, Turkey. After earning her medical degree from Hacettepe University, she has actively contributed to malignant hematology and stem cell transplantation research in Germany and the USA. She is passionate about translational science and fostering international collaboration, and currently holds the position of Co-chair of the EBMT Trainee Committee.
- [Soo Park](https://touchoncology.com/editorial-board/soo-park/): For Dr Soo Park is an Associate Professor of Medicine at the University of California San Diego, CA, USA. Dr Park specializes in non-melanoma skin cancers and is passionate about immune therapy and cancer prevention.
- [Rimas V Lukas](https://touchoncology.com/editorial-board/rimas-v-lukas/): Dr. Lukas is Vice Chair of Outpatient Neurology, Department of Neurology Associate Professor, Neurology (Neuro-oncology), Neurology (Hospital Neurology) at Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA. Dr. Lukas, sub-specializing in neuro-oncology, is interested in the care of patients with primary brain tumors and spinal cord tumors as well as central nervous system (CNS) metastases. Dr. Lukas's research centers on clinical trials in neuro-oncology. Additionally, he has a strong interest in medical education in the U.S. and internationally and conducts research in neuroscience medical education.
- [Dean A. Fennell](https://touchoncology.com/editorial-board/dean-a-fennell/)
- [Charlie Gourley](https://touchoncology.com/editorial-board/charlie-gourley/)
- [Véronique Diéras](https://touchoncology.com/editorial-board/veronique-dieras/): Senior Medical Oncologist, Department of Medical Oncology at Centre Eugène Marquis in Rennes, France
- [Winette van der Graaf](https://touchoncology.com/editorial-board/winette-van-der-graaf/): Professor van der Graaf became the president of the European Organisation for Research and Treatment of Cancer (EORTC) from March 2022. She has been administratively active within the board of the European Organisation for research and Treatment of Cancer (EORTC) and the Connective Tissue Oncology Society (CTOS) and is the chairman of the Dutch Sarcoma Group.
- [Emma Searle](https://touchoncology.com/editorial-board/emma-searle/): Consultant Haematologist, The Christie Hospital NHS Foundation Trust; Honorary Senior Lecturer, University of Manchester, Manchester, UK
- [Mohammad Ammad-Ud-Din](https://touchoncology.com/editorial-board/mohammad-ammad-ud-din/): Haematology/Oncology Fellow, Department of Internal Medicine, Moffitt Cancer Center, USF, Tampa, FL, USA
- [Ticiana Leal](https://touchoncology.com/editorial-board/ticiana-leal/): Dr Leal is a member of the American Society of Clinical Oncology, American Association for Cancer Research, Eastern Cooperative Oncology Group, European Society of Medical Oncology, Society for Immunotherapy of Cancer, and International Association for the Study of Lung Cancer. She is the NCI LUNG-MAP Chair, ECOG-ACRIN representative.
- [Inga	Peters](https://touchoncology.com/editorial-board/ingapeters/): Urologist; Senior Lecturer; Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany
- [Bruce D Minsky](https://touchoncology.com/editorial-board/bruce-d-minsky/): Professor Minsky is on the Board of Directors of the American Society of Radiation Oncology (ASTRO) and the American Society for Clinical Oncology (ASCO). He is a Fellow of both societies, is an honorary member of the European Society of Radiation Oncology (ESTRO) and was the 2015 President of ASTRO.
- [Marc Peeters](https://touchoncology.com/editorial-board/marc-peeters/): Professor Peeters is the secretary of the Flemish Society of Gastroenterology. He is treasurer of the Belgian Group of Digestive Oncology and member of the Belgian Society of Medical Oncology, The European Society of Medical Oncology, The American Society for Clinical Oncology and the gastrointestinal group of the European Organisation for Research and Treatment of Cancer.
- [Suchita Pakkala](https://touchoncology.com/editorial-board/suchita-pakkala/): Dr Pakkala is a member of American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH). 
- [Daniel Kelly OBE](https://touchoncology.com/editorial-board/daniel-kelly/): Professor Daniel Kelly has an academic background in the social sciences, nursing and health care. His research interests have focused on the impact and experience of illness – primarily reflecting his clinical and managerial experience in cancer and palliative care – as well as the future potential of nursing and associated NHS workforce issues. He is the fifth holder of the Royal College of Nursing Chair of Nursing Research at Cardiff University (Chair established in 1988). Professor Kelly is currently involved in national and international research projects, and is experienced as a PhD Supervisor and Examiner, including international examining.
- [Lena Sharp](https://touchoncology.com/editorial-board/lena-sharp/): Lena Sharp is the Head of the Regional Cancer Center, Stockholm, Sweden. She was previously the Chief Nursing Officer and Patient Safety Coordinator at the Department of Oncology, Karolinska University Hospital and has a long experience in cancer nursing, clinical work, leadership, teaching and research. Lena main research focus is Health Care Communication and Patient Safety. Lena has a Ph D from Karolinska Institute. Dr Sharp is President for European Oncology Nurses Society (EONS).
- [Mario Mandalà](https://touchoncology.com/editorial-board/mario-mandala/): Dr. Mario Mandalà received his medical degree from the Faculty of Medicine, Catholic University of Rome, Italy. He is currently Head of the Melanoma Unit, Division of Oncology at the Papa Giovanni XXIII Hospital in Bergamo, Italy. He was recently appointed Coordinator of the Mucosal and Ocular Melanoma Section of the Italian Rare Cancers Network. From 2011 he has chaired the scientific and organising committees of the Clinical and Translational Research Working Group of the Italian Melanoma Intergroup (IMI). Since 2008, he has given major contributions to ESMO, AIOM and ISTH clinical practice guidelines on the management of venous thromboembolism and solid tumours.
- [Shaji Kumar](https://touchoncology.com/editorial-board/shaji-kumar-md/): Dr Kumar receives ongoing support for research from the National Institutes of Health and the National Cancer Institute. He is a member of several professional societies, including the American Society of Hematology, American Society of Clinical Oncology, American Association for Clinical Research, American Society for Blood and Marrow Transplantation, American Medical Association, Association of Physicians of India, and the European Hematology Association. His work has appeared in peer-reviewed journals such as Lancet Oncology, Journal of Clinical Oncology, Blood Cancer Journal, Leukemia, American Journal of Hematology, Mayo Clinic Proceedings, Blood, and European Journal of Hematology. He received his medical degree from the All India Institute of Medical Sciences, New Delhi, India. He completed an internship there, followed by a clinical residency in internal medicine and a senior residency in medical oncology.
- [Bernardo Rapoport](https://touchoncology.com/editorial-board/bernardo-rapoport-2/): Dr Rapoport has presented more than 100 abstracts at South African and international meetings (including ASCO, MASCC and ESMO) and published more than 60 peer reviewed publications with over 2,000 citations. He is a reviewer for numerous scientific medical journals, including Annals of Oncology, Supportive Care in Cancer and Journal of Clinical Oncology.
- [Bertrand Tombal](https://touchoncology.com/editorial-board/bertrand-tombal/): Professor Bertrand Tombal is Chairman of the Division of Urology and Professor of Urology at the Université catholique de Louvain (UCL), Cliniques universitaires Saint-Luc, Brussels, Belgium. He is member of the Belgian Royal Academy of Medicine.
- [Ahmad Awada](https://touchoncology.com/editorial-board/ahmad-awada/): Dr Awada has published more than 27 book chapters, and more than 45 peer-review papers in international journals. His research focusses on new active anticancer drugs for solid tumours (new cytotoxics and molecular targeted therapies), and to individualize the treatments according to the tumour characteristics.

## Authors

## Press Releases
- [New Review Highlights the Latest Developments in Pediatric Anaplastic Large Cell Lymphoma](https://touchoncology.com/?press_release=new-review-highlights-the-latest-developments-in-pediatric-anaplastic-large-cell-lymphoma): LONDON, May 22, 2018 /PRNewswire/ --
- [Touch Digital Media Ltd Appoints Dr Brian Tempest as Non-Executive Chairman](https://touchoncology.com/?press_release=touch-digital-media-ltd-appoints-dr-brian-tempest-as-non-executive-chairman): Brian has worked in the pharmaceutical industry for the last 46 years in both the discovery and generic pharmaceutical industries. This has included Beecham, Glaxo, Searle, Fisons and Ranbaxy Laboratories. He has managed global pharmaceutical businesses around the world and, as CEO of a listed company, has presented at investor conferences from Las Vegas to Tokyo. Today Brian is also on the Governance Board of the United Nations Patent Pool and is a Non-Executive Independent Director of several companies in healthcare sectors including hospital management, medical diagnostics, packaging and pharmaceuticals. He is also Editor-in-Chief of the peer-reviewed Journal of Generic Medicines.
- [Touch Medical Media Announces Axel Merseburger as Editor-in-chief of European Oncology & Haematology](https://touchoncology.com/?press_release=touch-medical-media-announces-axel-merseburger-as-editor-in-chief-of-european-oncology-haematology): Professor Mersburger, who joined the European Oncology & Haematology Editorial Board last year, will become the first Editor-in-Chief of the journal. "It is a great honour and privilege to support European Oncology and Haematology as Editor-in-Chief. The Journal is delivered in two print issues per year (summer & winter), which gives the latest developments in haematology and oncology, as well as ePub ahead of print throughout the year. It is exciting to work with the international, multidisciplinary editorial board providing you the recent developments in their field. The journal will further invest in including up-to-date, high-quality, and original contributions - research papers, as well as reviews, and conference reviews," said Merseburger following his appointment.
- [New Review of Advancing our Clinical Perspectives in Haematology – What is Your Approach?](https://touchoncology.com/?press_release=new-review-of-advancing-our-clinical-perspectives-in-haematology-what-is-your-approach): Published recently in European Oncology & Haematology Review, the peer-reviewed journal from touchONCOLOGY, James Gilbart discusses Essential thrombocythaemia (ET) which is a rare and serious blood disorder that is associated with significant morbidity and mortality, but knowledge of the pathophysiology and best approaches to its management are evolving. It is important that myeloproliferative neoplasms are differentiated from each other as they differ in treatment approaches. It is also important to perform a bone marrow biopsy and identify the mutations causing ET since these affect prognostic factors such as thrombosis-free survival. In ET, 50-60% of patients have a mutation in the Janus kinase gene, 5-10% in the thrombopoetin receptor and 20% in the calreticulin gene. There is, however, a lack of consensus in ET regarding the optimum tests to perform and the most appropriate management approach. Signs and symptoms in ET are variable, the condition often has cutaneous manifestations such as pruritus leading to ulcers and phlebitis and such symptoms should be investigated. Cytoreductive therapies for ET include hydroxcarbamide, anagrelide and busulphan but treatment regimens vary according to patient age and must be carefully monitored and should be changed to maintain tolerability and quality of life. In women, the thrombotic risks in ET can be increased by contraception, pregnancy and menopause. In the elderly with ET, cardiovascular risk factors and cardiovascular events are serious complications that can be minimised by controlling factors such as blood pressure, blood glucose and cholesterol. Increased awareness of ET, willingness to perform diagnostic tests and prompt initiation of appropriate treatments are likely to increase detection of the condition and improve outcomes.
- [New Review of Optimising Clinical Outcomes in Gastrointestinal Cancers Through Inhibiting Angiogenesis and Other Signalling Pathways](https://touchoncology.com/?press_release=new-review-of-optimising-clinical-outcomes-in-gastrointestinal-cancers-through-inhibiting-angiogenesis-and-other-signalling-pathways): Published recently in a supplement to European Oncology & Haematology Review, the peer-reviewed journal from touchONCOLOGY, an article by James Gilbart and Axel Grothey emphasises that both metastatic colorectal cancer (mCRC) and hepatocellular cancer (HCC) are complex diseases. During progression, they frequently become refractory to treatment and patients are likely to receive a series of different chemotherapy regimens. The multikinase inhibitors (MKIs) have considerable potential in mCRC and HCC treatment and can extend overall and disease-free survival in advanced disease. Clinical experience of some of the newer MKIs in mCRC and HCC is, however, limited. The phase III CORRECT (n=760) and CONCUR (n=204) trials showed that in patients who failed with previous therapy, overall survival (OS) and progression-free survival (PFS) were significantly increased with the MKI, regorafenib compared with placebo (both given with best supportive care). Similar findings were reported in the CONSIGN trial (n=2,872) that assessed regorafenib efficacy in real-world mCRC patients. In CORRECT and CONCUR the objective response rate was low (1-4%) but stable disease was achieved in much greater proportions (40-47%). This indicates that the suitability of some therapeutic goals may need to change after disease progression. Studies have also indicated the potential of biomarkers such as carcinoembryonic antigen, carbohydrate antigen 19-9 and the consensus molecular subtype in identifying patients who are more suitable for MKI treatment. Results of the RESOURCE study (n=573) show that regorafenib significantly improves OS, PFS and time to progression in HCC compared with placebo. These positive benefits are in contrast to the negative results of many previous trials of other treatments in HCC. Greater use of MKIs, alternating them with other therapies, expanded guidelines for managing disease progression and the identification of biomarkers are likely to improve the otherwise bleak prospects and outcomes in mCRC and HCC. This article reports presentations given at a satellite symposium convened at the European Society for Medical Oncology 18th World Congress on Gastrointestinal Cancer, Barcelona 2nd July 2016.  
- [New Review of Cancer Immunotherapy With Interleukin-2- Current Status and Future Developments](https://touchoncology.com/?press_release=new-review-of-cancer-immunotherapy-with-interleukin-2-current-status-and-future-developments): Published recently in Oncology & Hematology Review, the peer-reviewed journal from touchONCOLOGY, Shilpa Gupta discusses high-dose interleukin-2 (HD IL-2), which has been in clinical use in the treatment of metastatic renal cell carcinoma (mRCC) and metastatic melanoma (mM) for over 20 years, and has produced substantial, durable responses in selected patients, resulting in cures in some patients with no ongoing therapy or chronic toxicity. However, use of the drug has remained limited owing to its significant acute toxicities, and the fact that only a minority of selected patients derive a response to treatment. Recent registry data support the use of HD IL-2 as first-line therapy in mRCC and mM, producing major responses for some and thus reducing the requirement for long-term therapy. In addition, an enhanced understanding of the role of IL-2 has led to the development of new therapeutic approaches to maximize the anti-tumor response of IL-2. These strategies include combined treatment with vaccines, antibody treatments to block inhibitory pathways, or adoptive cell transfer of T cells. These data and new approaches have led to continued use of HD IL-2 and may increase the number of patients who derive benefit from this treatment.
- [How to Find the Optimal Mobilisation Strategy for Haematopietic Stem Cells – Impact, Challenges and Solutions](https://touchoncology.com/?press_release=how-to-find-the-optimal-mobilisation-strategy-for-haematopietic-stem-cells-impact-challenges-and-solutions): Disclosure: Patrick Wuchter is an Advisory Board member and has received honoraria from Sanofi-Aventis. He is an Advisory Board member and has received travel grants from Hexal AG. Kai Hubel is an Advisory Board member and received honoraria from Sanofi-Aventis, Roche, Gilead, Teva, Hexal, Celgene and Amgen.
- [Optimising the Use of Ruxolitinib in Inadequately Controlled Polycythaemia Vera](https://touchoncology.com/?press_release=optimising-the-use-of-ruxolitinib-in-inadequately-controlled-polycythaemia-vera): Published recently in European Oncology & Haematology Review, the peer-reviewed journal from touchONCOLOGY, Jean-Jacques Kiladjian et al, present a review of polycythaemia vera (PV), an uncommon chronic myeloproliferative neoplasm characterised by increased red-cell mass. The condition is currently managed by phlebotomy and/or palliative cytoreductive therapy, most commonly using hydroxyurea (HU). However, around 25% of patients have an inadequate response and/or unacceptable adverse effects; furthermore, patients with resistance to HU appear to have shorter survival than other patients with PV. Recently, a second-line treatment has become available. Ruxolitinib, an oral inhibitor of the Janus kinase (JAK) 1 and JAK 2 tyrosine kinases, has recently received regulatory approval for the treatment of patients with PV who are resistant to or intolerant of HU. This treatment offers the potential to significantly reduce phlebotomy requirements and improve the symptom burden. However, in order to determine which patients will benefit most from ruxolitinib, it is necessary to identify those who are inadequate responders to HU, a definition that is not currently consensual in the literature. Five patient groups, for whom ruxolitinib may be a beneficial second-line treatment option, have been proposed. These comprise patients who are at high risk and retain a high symptom burden after HU, require frequent phlebotomy, have an elevated leukocyte count, are intolerant to HU or interferon, or have palpable splenomegaly.
- [Does Interleukin 2 Still Have a Role in Cancer Immunotherapy? – The PROCLAIM[SM] Registry](https://touchoncology.com/?press_release=does-interleukin-2-still-have-a-role-in-cancer-immunotherapy-the-proclaimsm-registry): Disclosure: Howard L Kaufman has served on advisory boards for Prometheus. This article is a short opinion piece and has not been submitted to external peer reviewers, but was reviewed by the Editorial Board before publication.
- [Unique Role of Anti-Human T-lymphocyte Immune Globulin in the Prevention of Chronic Graft-versus-host Disease](https://touchoncology.com/?press_release=unique-role-of-anti-human-t-lymphocyte-immune-globulin-in-the-prevention-of-chronic-graft-versus-host-disease): Disclosure: Nicolaus Kröger received research grant from Neovii Pharmaceuticals AG.
- [Treatment Update for Hormone Receptor-Positive Advanced Breast Cancer](https://touchoncology.com/?press_release=treatment-update-for-hormone-receptor-positive-advanced-breast-cancer): Published recently in European Oncology & Haematology Review, the peer-reviewed journal from touchONCOLOGY, Karen A Gelmon draws attention to the urgent need for new treatments for advanced cancer of the breast, of which the most common subtype is hormone receptor positive breast cancer. In the randomised, double-blind, multicentre phase III trial, Fulvestrant and AnastrozoLe COmpared in hormonal therapy Naïve advanced breast cancer (FALCON), a statistically significant 21% reduction in the risk of disease progression or death was reported in women with hormone receptor-positive advanced breast cancer who had been treated with fulvestrant compared with those who had received anastrozole. Women in this study had not received prior hormone therapy. Access to the treatment and the mechanisms for funding need to be facilitated in a timely fashion. Ongoing studies are awaited to help define the optimal sequence of therapy for women with hormone receptor-positive advanced breast cancer.
- [Epigenetics: A New Approach for the Treatment of Multiple Myeloma](https://touchoncology.com/?press_release=epigenetics-a-new-approach-for-the-treatment-of-multiple-myeloma): Published recently in European Oncology & Haematology Review, the peer-reviewed journal from touchONCOLOGY, Andrew Spencer et al, highlights the critical need for more effective therapies in multiple myeloma (MM) since all patients eventually relapse following front-line treatment. A variety of both genetic and epigenetic abnormalities may be present in MM, the latter including DNA and histone methylation and histone deacetylation, and are thought to contribute to the pathogenesis of the disease. For example, global methylation analysis in MM has identified inactivated tumour suppressor genes that are prognostically important. Through their ability to acetylate histones and cytoplasmic proteins, histone deacetylases (HDAC) influence a wide variety of cellular functions, such as proliferation, differentiation and apoptosis. Increased class 1 HDAC expression has been linked in solid tumours with more locally advanced, de-differentiated and proliferative tumours, and with poor prognosis in MM. HDAC inhibitors, panobinostat and ricolinostat, have been demonstrated to be effective in combination with bortezomib and dexamethasone in newly diagnosed patients with MM and in heavily pre-treated patients with advanced MM. HDAC inhibitor-monoclonal antibody combinations are also being explored. The potential of HDAC inhibitors to improve outcome for patients with MM is evident but a greater understanding of their anti-tumour effects is needed.
- [New Review of Rociletinib-An Investigational Therapy in Patients With Previously Treated EGFR Mutant-positive Non-small Cell Lung Cancer     Google+     Share with LinkedIn   r](https://touchoncology.com/?press_release=new-review-of-rociletinib-an-investigational-therapy-in-patients-with-previously-treated-egfr-mutant-positive-non-small-cell-lung-cancer-google-share-with-linkedin-r): LONDON, December 22, 2015 /PRNewswire/ --
- [New-generation Genomic Test for Treatment Decision-making in Early Breast Cancer – Contribution of the Prosigna® (PAM50) Gene Signature Assay](https://touchoncology.com/?press_release=new-generation-genomic-test-for-treatment-decision-making-in-early-breast-cancer-contribution-of-the-prosigna-pam50-gene-signature-assay): LONDON, November 10, 2015 (PRNewswire) European Oncology & Haematology Review, a peer-reviewed journal, has published a review highlighting the benefits of the Prosigna® (PAM50) Gene Signature Assay, a new-generation genomic test for treatment decision-making in early breast cancer
- [New Review of Adverse Event Management in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer](https://touchoncology.com/?press_release=new-review-of-adverse-event-management-in-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer): LONDON, October 15, 2015 /PRNewswire/ - European Oncology & Haematology Review, the peer-reviewed journal, has published a review highlighting the Adverse Event Management in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
- [New Study in A Rare Condition in Haematological Practice – Gaucher Disease](https://touchoncology.com/?press_release=new-study-in-a-rare-condition-in-haematological-practice-gaucher-disease): (PRWEB UK) 2 June 2015 -- European Oncology & Haematology, a peer-reviewed, open access, bi-annual oncology journal published a cutting-edge article by Maria-Domenica Cappellini.
- [(PRWEB UK) 22 January 2015](https://touchoncology.com/?press_release=prweb-uk-22-january-2015): Touch Medical Media, the Provider of Peer-reviewed, Open Access and Multimedia Content, Launch Mobile Optimised Websites Across Their Online Physician Communities.
- [New Research Looks at Immunologic Therapy of Renal Cell Carcinoma](https://touchoncology.com/?press_release=new-research-looks-at-immunologic-therapy-of-renal-cell-carcinoma): June 03, 2014 -- Oncology & Hematology Review, the peer-reviewed journal, publishes cutting-edge article on Immunologic Therapy of Renal Cell Carcinoma.
- [London (PRWEB UK) 24 October 2013](https://touchoncology.com/?press_release=london-prweb-uk-24-october-2013): London (PRWEB UK) 24 October 2013 - touchONCOLOGY were circulating copies of their latest edition of European Oncology & Haematology Review Volume 9 Issue 1, a free-to-access, peer-reviewed journal aimed at the European market, made up of cutting-edge review articles written by some of the most respected physicians in the world.
- [London, UK (PRWEB UK) 6 August 2013 — At the same time](https://touchoncology.com/?press_release=london-uk-prweb-uk-6-august-2013-at-the-same-time): London, UK (PRWEB UK) 6 August 2013 -- At the same time, Touch Medical Media has signed an updated licensing agreement with Doctors.net.uk, the UK’s largest and most active network of medical professionals, which will see the latter’s 198,000 members gain access to scientific peer-reviewed content across Touch Oncology and Touch Endocrinology globally
- [touchONCOLOGY, the provider of peer-reviewed](https://touchoncology.com/?press_release=touchoncology-the-provider-of-peer-reviewed): touchONCOLOGY, the provider of peer-reviewed, multimedia content from world renowned physicians, profile their re-launched website and latest journal at ASCO 2013
- [Touch Medical Media](https://touchoncology.com/?press_release=touch-medical-media): Touch Medical Media splits from Touch Briefings, launches a series of cutting edge, free to access, educational resources and signs an updated media partnership with ECCO, The European CanCer Organisation, a pan-European federation representing 60,000 oncology professionals.

## Hubs
- [Neurofibromatosis type 1](https://touchoncology.com/cme/hub/neurofibromatosis-type-1/)
- [Recurrent/metastatic nasopharyngeal carcinoma](https://touchoncology.com/cme/hub/recurrent-metastatic-nasopharyngeal-carcinoma/)

## Podcasts
- [Who’s on your bench? The five people every high performer needs](https://touchoncology.com/podcast/whos-on-your-bench-the-five-people-every-high-performer-needs/): Your clinical career is shaped not only by what you know, but by who helps you navigate what comes next. Join us for the final episode in our mini-series exploring non-clinical skills that can help you thrive in your clinical career. Today we explore how to develop the right team around you to support your work, and what building that bench can mean for your career, and the life you build alongside it.
- [A clinician’s guide to building meaningful media relationships](https://touchoncology.com/podcast/building-media-relationships/): We often focus on clinical excellence, but spend less time developing broader skills that could help us better lead with purpose and build more fulfilling, impactful careers. In this episode, part of a mini-series in partnership with LEADderm, Dr Jennifer Soung and Denise Mann explore how clinicians can engage with the media to educate, empower and extend their impact beyond the clinic.
- [Is pharma for me? Navigating the move from agency, clinic or academia](https://touchoncology.com/podcast/is-pharma-for-me/): Whether you’re working in an agency, in a clinical role, or in academia, many healthcare professionals wonder what lies behind the doors of the pharmaceutical industry. In this episode, Gina is joined by Sian Kneller, Director of Global Content Design at GSK and Founder of The Agency Advantage, to unpack exactly what it takes to make the leap. With over 20 years’ experience, from medical writer to leading global medical affairs strategy, Sian now helps others make a successful move into pharma. In this episode she shares what the transition really looks like, which transferable skills matter most, and how you can stand out in a competitive field.
- [Could senolytics change the treatment landscape of age-related diseases?](https://touchoncology.com/podcast/senolytics-age-related-diseases/): In this episode, Nicky speaks with Prof. Georgina Ellison-Hughes from King’s College London about the groundbreaking field of senolytics and their potential to advance the treatment of age-related diseases. From understanding the science behind cellular senescence to how senolytic drugs work and what early clinical trials reveal, this episode explores an exciting frontier in longevity medicine.
- [What impact does sleep have on physicians and their patients?](https://touchoncology.com/podcast/impact-sleep-physicians-patients/): In this episode of Visionary Voices, we welcome Associate Professor Grace Vincent from CQUniversity’s Appleton Institute. A leading expert on sleep and shift work, Grace explores how disrupted rest impacts physician health in both the short and long term, safety and performance. We also discuss what this means for patient outcomes and share practical strategies to manage sleep loss.
- [Why are so many physicians burning out, and how can we break the cycle?](https://touchoncology.com/podcast/why-are-so-many-physicians-burning-out-and-how-can-we-break-the-cycle/): Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more supportive healthcare culture.
- [What’s on the horizon for continuing medical education? Insights from touchIME](https://touchoncology.com/podcast/whats-on-the-horizon-for-continuing-medical-education-insights-from-touchime/): In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
- [Space medicine: Can microgravity transform pharmaceutical manufacturing?](https://touchoncology.com/podcast/space-medicine-can-microgravity-transform-pharmaceutical-manufacturing/): In our latest episode, we delve into the world of space medicine to explore how drug crystallization in microgravity could revolutionize biologic drug administration. Joining us is Dr Katie King, CEO of BioOrbit, to discuss the science, challenges, and technological advancements that could make space-based drug production a reality.
- [Laying the groundwork for medical breakthroughs: The MPN-RC blueprint](https://touchoncology.com/podcast/laying-the-groundwork-for-medical-breakthroughs-the-mpn-rc-blueprint/): Few alliances have impacted patient care as significantly as the Myeloproliferative Neoplasms Research Consortium (MPN-RC). Established in 2006, the MPN-RC is an international group dedicated to advancing research and developing innovative treatment strategies for myeloproliferative neoplasms. In this episode, we speak with Prof. John Mascarenhas, about the coalition's founding, operational mechanics and how their efforts have led to paradigm-shifting therapies in the field.

## Conference Hub
- [Upfront PARP inhibition in mHSPC: Key findings from the TALAPRO-3 trial](https://touchoncology.com/genitourinary-cancers/conference-hub/upfront-parp-inhibition-in-mhspc-key-findings-from-the-talapro-3-trial/): touchONCOLOGY coverage of ASCO 2026
- [#ASCO25: ATOMIC trial shows atezolizumab halves recurrence in stage III dMMR colon cancer](https://touchoncology.com/colorectal-cancer/conference-hub/asco25-atomic-trial-shows-atezolizumab-halves-recurrence-in-stage-iii-dmmr-colon-cancer/): Dr Frank Sinicrope presented results from the ATOMIC trial at #ASCO25, showing that adding atezolizumab to adjuvant FOLFOX halved the risk of recurrence or death in stage III dMMR colon cancer. With no major safety concerns, the findings support chemo-immunotherapy as a new standard of care for this patient group.
- [#ASCO25 late-breaker: How vepdegestrant could reshape ER+ breast cancer](https://touchoncology.com/breast-cancer/conference-hub/asco25-late-breaker-how-vepdegestrant-could-reshape-er-breast-cancer/): The VERITAC-2 trial is a pivotal, randomized phase III trial evaluating vepdegestrant, a novel oral PROTAC estrogen receptor degrader, in patients with ER-positive, HER2-negative advanced breast cancer. In this interview, Dr Erika Hamilton (Director, Breast Cancer Research, Sarah Cannon Research Institute, Nashville, TN, USA) discusses the rationale behind VERITAC-2, the unique mechanism of PROTAC degraders, and what the data could mean for future treatment strategies.
- [#ASCO25: Sacituzumab combination shows promise in PD-L1+ TNBC in the ASCENT-04 study](https://touchoncology.com/breast-cancer/conference-hub/asco25-sacituzumab-combination-shows-promise-in-pd-l1-tnbc-in-the-ascent-04-study/): Dr. Sara Tolaney discusses ASCENT-04, a phase III trial showing that sacituzumab govitecan plus pembrolizumab significantly improves progression-free survival versus chemotherapy plus pembrolizumab in PD-L1–positive metastatic TNBC. With a PFS of 11.2 months and a hazard ratio of 0.65, the combination may represent a new first-line treatment standard.
- [#ASCO25: T-DXd plus pertuzumab doubles PFS in HER2+ in DESTINY-Breast09](https://touchoncology.com/breast-cancer/conference-hub/asco25-t-dxd-plus-pertuzumab-doubles-pfs-in-her2-in-destiny-breast09/): DESTINY-Breast09 interim results show that trastuzumab deruxtecan plus pertuzumab significantly improves progression-free survival compared to standard THP in first-line treatment for metastatic HER2-positive breast cancer. With a median PFS of 40.7 months versus 26.9 months, the data suggest a potential shift in the treatment paradigm.
- [Niraparib as first-line maintenance treatment in ovarian cancer](https://touchoncology.com/gynecologic-cancers/conference-hub/niraparib-as-first-line-maintenance-treatment-in-ovarian-cancer/): The phase III PRIMA/ENGOT-OV26/GOG-3012 trial evaluated the efficacy of niraparib as a first-line maintenance treatment for patients with advanced ovarian cancer who responded to platinum-based chemotherapy. In this final analysis, no significant difference in overall survival was observed between niraparib and placebo in the overall or homologous recombination-deficient (HRd) populations. However, long-term progression-free survival and time to first subsequent therapy were significantly improved with niraparib, particularly in patients in the HRd subgroup. Safety outcomes were consistent with the known profile, and no new safety concerns were observed.
- [Capivasertib + paclitaxel for metastatic triple-negative breast cancer did not meet threshold for improving overall survival](https://touchoncology.com/breast-cancer/conference-hub/capivasertib-paclitaxel-for-metastatic-triple-negative-breast-cancer-did-not-meet-threshold-for-improving-overall-survival/): The phase III CAPItello-290 trial assessed the combination of capivasertib (C) with paclitaxel (P) as a first-line treatment for metastatic triple-negative breast cancer compared to paclitaxel plus placebo. A total of 812 patients were enrolled, with 30.7% showing PIK3CA/AKT1/PTEN alterations. While progression-free survival slightly favoured the C+P combination, the primary endpoint of overall survival was not met in either the overall population or the altered gene subgroup. Common adverse events included diarrhoea and anaemia, with a manageable safety profile. Further research is needed to explore the clinical potential.
- [Trastuzumab deruxtecan shows clinical benefit in patients with HER2-ultralow metastatic breast cancer](https://touchoncology.com/breast-cancer/conference-hub/trastuzumab-deruxtecan-shows-clinical-benefit-in-patients-with-her2-ultralow-metastatic-breast-cancer/): he DESTINY-Breast06 (DB-06) trial explored the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with hormone receptor-positive (HR+), HER2-low or HER2-ultralow metastatic breast cancer (mBC). Patients were screened for HER2 status and randomized to receive either T-DXd or treatment of the physician's choice (TPC). Results showed that T-DXd significantly improved progression-free survival (PFS) compared to TPC, across various HER2 classifications.
- [Durvalumab with neoadjuvant chemotherapy and radical cystectomy in muscle-invasive bladder cancer](https://touchoncology.com/bladder-cancer/conference-hub/durvalumab-with-neoadjuvant-chemotherapy-and-radical-cystectomy-in-muscle-invasive-bladder-cancer/): The NIAGARA trial evaluated the combination of durvalumab (D) with neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) and adjuvant durvalumab in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). A total of 1063 patients were randomized to either receive durvalumab + NAC + RC followed by adjuvant durvalumab or NAC + RC alone. The study showed a significant improvement in event-free survival (EFS) and overall survival (OS) in the durvalumab arm compared to NAC alone (EFS hazard ratio 0.68; OS HR 0.75). The safety profile was consistent across both study groups, and the addition of durvalumab did not interfere with the completion of RC.
- [Nivolumab plus Relatlimab alongside chemotherapy demonstrated improved clinical benefit in the RELATIVITY-104 trial](https://touchoncology.com/lung-cancer/conference-hub/nivolumab-plus-relatlimab-alongside-chemotherapy-demonstrated-improved-clinical-benefit-in-the-relativity-104-trial/): The phase II RELATIVITY-104 trial assessed the combination of nivolumab (NIVO) and relatlimab (RELA), a LAG-3-blocking antibody, alongside chemotherapy (PDCT) as a first-line treatment for metastatic non-small cell lung cancer (NSCLC). In this randomized trial, patients receiving NIVO + RELA + PDCT demonstrated a higher overall response rate (ORR) (51.3%) compared to NIVO + PDCT (43.7%). Progression-free survival (PFS) showed trends favouring NIVO + RELA, especially in patients with PD-L1 ≥1% and non-squamous histology. Safety profiles were consistent with previous studies, showing manageable adverse events. Further phase III investigation is needed to confirm these results.
- [Addition of nivolumab to rucaparib did not improve clinical outcomes in newly diagnosed, advanced, high-grade ovarian cancer](https://touchoncology.com/gynecologic-cancers/conference-hub/addition-of-nivolumab-to-rucaparib-did-not-improve-clinical-outcomes-in-newly-diagnosed-advanced-high-grade-ovarian-cancer/): The ATHENA trial evaluated the effectiveness of rucaparib (RUCA) monotherapy (MONO) and rucaparib combined with nivolumab (NIVO) (COMBO) in patients with advanced high-grade ovarian cancer (AHGOC). In the MONO arm, rucaparib showed sustained progression-free survival (PFS) of 20.2 months after first-line treatment. However, the COMBO arm did not improve PFS, with median PFS being shorter than in MONO (15.0 vs 20.2 months). The study also explored subgroups with homologous recombination deficiency (HRD) and PD-L1 expression. COMBO had more frequent treatment-related adverse events, but the safety profiles were consistent with previous studies.
- [Transarterial chemoembolization with lenvatinib and pembrolizumab showed improvement in progression-free survival for hepatocellular carcinoma](https://touchoncology.com/gastrointestinal-cancers/conference-hub/transarterial-chemoembolization-with-lenvatinib-and-pembrolizumab-showed-improvement-in-progression-free-survival-for-hepatocellular-carcinoma/): touchONCOLOGY coverage of data presented at European Society of Medical Oncology (ESMO) 2024 Annual Congress
- [ESGO 24: Advances in cervical, endometrial and ovarian cancer](https://touchoncology.com/gynecologic-cancers/conference-hub/insights-and-highlights-of-esgo-2024/): The annual European Society of Gynaecological Oncology (ESGO) Congress, held from 7–10 March 2024, in Barcelona, Spain, celebrated its 25th anniversary this year. This year’s congress brought together over 2,500 participants from all over the world, and featured groundbreaking research, clinical advancements and professional development opportunities.
- [Breast cancer highlights: DESTINY-Breast06, postMONARCH, TBCRC 048](https://touchoncology.com/breast-cancer/conference-hub/highlights-in-breast-cancer-destiny-breast06-postmonarch-tbcrc-048-olaparib-expanded-sara-tolaney-asco-2024/): Providing valuable insights into the findings from key studies including DESTINY-Breast06 (NCT04494425), postMONARCH (NCT05169567), and TBCRC 048 (olaparib expanded) (NCT02032823), Dr. Tolaney explores the potential impact these results could have on clinical practice.
- [Key insights in gynecological malignancies: BrUOG 354, AGO-OVAR 2.29/ENGOT-ov34, KEYVIBE-005, CARACO](https://touchoncology.com/gynecologic-cancers/conference-hub/highlights-in-gynecological-malignancies-bruog-354-ago-ovar-2-29-engot-ov34-keyvibe-005-caraco-domenica-lorusso-asco-2024/): To further understand the key developments and research presented in the field of gynaecological oncology at ASCO 2024, we spoke with Dr. Domenica Lorusso, Professor of Obstetrics and Gynaecology at Humanitas University of Milan, Italy. In this interview, Dr. Lorusso discusses the findings from the BrUOG 354 (NCT03355976), AGO-OVAR 2.29/ENGOT-ov34 (NCT03353831), KEYVIBE-005 (NCT05007106), and CARACO (NCT01218490) trials, offering her valuable insights into the potential impact these results could have on clinical practice.
- [Key data in gastrointestinal cancer: ESOPEC, TRANSMET, COLLISION, ARC-9](https://touchoncology.com/colorectal-cancer/conference-hub/highlights-in-gastrointestinal-cancer-esopec-transmet-collision-arc-9-michael-cecchini-asco-2024/): Practice-changing data in the field of gastrointestinal cancer was presented at ASCO 2024. To understand these, as well as the other highlights from the meeting, we spoke with Assistant Professor of Medicine (Medical Oncology), Yale School of Medicine, Dr Michael Cecchini. In this interview, Dr Cecchini discusses the findings from the ESOPEC (NCT02509286), TRANSMET (NCT02597348), COLLISION (NCT03088150), ARC-9 (NCT04660812), ABBV-400 (NCT05029882) and other presentations, offering his valuable insights into the impact the results could have on clinical practice.
- [Focus on leukemia – Felix and ASC4FIRST](https://touchoncology.com/hematologic-malignancies/conference-hub/highlights-in-leukemia-felix-asc4first-elias-jabbour-asco-2024/): The open-label, single-arm phase Ib/II Felix  study (NCT04404660) investigated obecabtagene autoleucel (obe-cel, AUTO1), a novel anti-CD19 autologous CAR-T cell therapy, in adults with relapsed/refractory B-cell acute lymphoblastic leukemia.  The results suggest that obe-cel can provide long-term remission without necessarily needing a transplant. touchONCOLOGY spoke with editorial board member, Elias Jabbour (MD Anderson Cancer Center, Houston, TX, USA), who summarized the key take-home messages from his presentation at ASCO 2024. Dr Jabbour also discussed the findings from the ASC4FIRST trial (NCT04971226).
- [Insights in bladder cancer: EV-302, EV-101, CheckMate 901](https://touchoncology.com/bladder-cancer/conference-hub/highlights-in-bladder-cancer-ev-302-ev-101-checkmate-901-petros-grivas-asco-2024/): Significant advancements in bladder cancer research emerged from ASCO 2024. To understand these, as well as the other key trials and highlights from the meeting, we spoke with the Clinical Director of the Genitourinary Cancer Program at the University of Washington and Fred Hutchinson Cancer Center, Prof. Petros Grivas. In this interview, Prof. Grivas delves into the findings from the EV-302 (NCT04223856), EV-101 (NCT02091999), EV-201 (NCT03219333), EV-301 (NCT03474107), CheckMate 901 (NCT03036098) and other trials, offering his valuable insights into the impact the results could have on clinical practice, and particularly in the treatment of bladder
- [PERSEUS trial results: Daratumumab + VRd in newly diagnosed multiple myeloma: ASH 2023, Pieter Sonneveld](https://touchoncology.com/hematologic-malignancies/conference-hub/perseus-trial-results-daratumumab-vrd-in-newly-diagnosed-multiple-myeloma-ash-2023-pieter-sonneveld/): The randomized phase III PERSEUS trial (NCT03710603) investigated daratumumab in combination with bortezomib, lenalidomide, and dexamethasone (VRd) compared with VRd and lenalidomide alone in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM). Daratumumab, a CD38 monoclonal antibody, is currently approved for use in several treatment regimens aimed at both transplant-eligible and non-transplant-eligible NDMM. In this interview Prof. Pieter Sonneveld (Erasmus MC Cancer Institute, Rotterdam, Netherlands) kindly joins us to discuss the current treatment landscape for NDMM and the role of autologous stem cell transplantation; the PERSUEUS trial rationale, design and key findings, highlighting potential implications of the results for the future treatment of NDMM.
- [Top 3 highlights from EONS16: Virpi Sulosaari](https://touchoncology.com/supportive-cancer-care/conference-hub/top-3-highlights-from-eons16-virpi-sulosaari/): This year, in partnership with ESMO23, the European Oncology Nurses Society (EONS) held its annual meeting - EONS16.
- [Upper gastrointestinal cancer highlights – KEYNOTE-585, KEYNOTE-811, MATTERHORN and SANO: Ken Kato, ASCO 2023](https://touchoncology.com/gastrointestinal-cancers/conference-hub/upper-gastrointestinal-cancer-highlights-keynote-585-keynote-811-matterhorn-and-sano-ken-kato-asco-2023/): Data released from the KEYNOTE-585 (NCT03221426), KEYNOTE-811 (NCT03615326), MATTERHORN (NCT04592913) and SANO (NCT05491616) trials, were some of the most anticipated results and highlights in upper gastrointestinal cancer presented at EMSO 2023.
- [Highlights in genitourinary cancers (non-prostate) – SunRISe-1, THOR-2, EV-302 CheckMate 901: Petros Grivas, ESMO 2023](https://touchoncology.com/genitourinary-cancers/conference-hub/genitourinary-cancer-highlights-sunrise-1-thor-2-ev-302-checkmate-901-petros-grivas-esmo-2023/): ESMO 2023 brought forth some practice-changing data in the field of non-prostate genitourinary cancer. To understand these, as well as the other key trials and highlights from the meeting, we engaged in a conversation with the Clinical Director of the Genitourinary Cancer Program at the University of Washington and Fred Hutchinson Cancer Center, Prof. Petros Grivas.
- [Top 5 tips for a successful career in medical oncology: Petros Grivas, ESMO 2023](https://touchoncology.com/genitourinary-cancers/conference-hub/top-5-tips-for-a-successful-career-in-medical-oncology-petros-grivas-esmo-2023/): As part the Young Oncologists session, at ESMO 2023, Prof. Petros Grivas (Clinical Director of the Genitourinary Cancer Program, University of Washington and Fred Hutchinson Cancer Center, Seattle, USA) and colleagues, spent time speaking with medial students and early-career physicians about developing a successful career in medial oncology. 
- [Highlights in breast cancer  – KEYNOTE-756, Checkmate-7FL, TOPION-Breast01, monarchE: Sara Tolaney, ESMO 2023](https://touchoncology.com/breast-cancer/conference-hub/breastcancerhighlightsesmo/): Significant advancements in breast cancer research emerged from ESMO 2023. To highlight these key data we spoke with prominent breast medical oncologist, Dr. Sara Tolaney (Dana-Farber Cancer Institute, Boston).
- [Durvalumab + tremelimumab vs. doxorubicin in soft tissue sarcoma – MEDISARC study: Viktor Grünwald, ESMO 2023](https://touchoncology.com/sarcoma/conference-hub/durvalumab-tremelimumab-vs-doxorubicin-in-soft-tissue-sarcoma-medisarc-study-viktor-grunwald-esmo-2023/): To further understand the potential of durvalumab (DUR) plus tremelimumab (TRE) in the treatment of soft tissue sarcoma (STS) we spoke with Prof. Viktor Grünwald (University Hospital Essen, Germany).
- [ARPi vs. SOC and taxanes in mCRPC – ProBio study: Henrik Grönberg, EMSO 2023](https://touchoncology.com/prostate-cancer/conference-hub/arpi-vs-soc-and-taxanes-in-mcrpc-probio-study-henrik-gronberg-emso-2023/): The uniquely designed Prostate Biomarker (ProBio) study (NCT03903835) used outcome-adaptive randomization to compare biomarker-driven treatment selection against physician’s choice, and to compare androgen receptor inhibitors (ARPIs) against standard-of-care (SOC) and taxanes in castrate-resistant prostate cancer (mCRPC).
- [Highlights in gynaecological oncology: Domenica Lorusso, ESMO 2023](https://touchoncology.com/gynecologic-cancers/conference-hub/highlights-in-gynaecological-oncology-domenica-lorusso-esmo-2023/): To further understand the key developments and research presented in the field of gynaecological oncology at ESMO 2023, we spoke with Dr Domenica Lorusso, Professor of Obstetrics and Gynaecology at the Fondazione Policlinico Universitario Agostino Gemelli - UCSC Italy.
- [Tarlatamab in pre-treated SCLC – DeLLphi-301 study: Luis Paz-Ares, EMSO 2023](https://touchoncology.com/lung-cancer/conference-hub/phase-2-results-of-tarlatamab-in-pre-treated-sclc-dellphi-301-study-luis-paz-ares-emso-2023/): The anticipated phase 2 data from the DeLLphi-301 study (NCT05060016), investigating the antitumor activity and safety of taralatamab administered at two doses in pre-treated small cell lung cancer (SCLC), were presented at this year’s EMSO meeting. 
- [Trastuzumab duocarmazine in HER2+ metastatic breast cancer – TULIP trial results: Philippe Aftimos, ESMO 2023](https://touchoncology.com/breast-cancer/conference-hub/__trashed/): The final results of the phase 3, TULIP trial (NCT03262935), which compared trastuzumab duocarmazine (T-Duo) with physician's choice of therapy in previously treated HER2-positive metastatic breast cancer, were presented at ESMO 2023. 
- [Raising awareness around HPV infection, cancer risk and vaccination: PrEvCan | Daniel Kelly](https://touchoncology.com/policy/conference-hub/raising-awareness-around-hpv-infection-cancer-risk-and-vaccination-prevcan-daniel-kelly/): This August, the PrEvCan campaign focuses on raising awareness about the connection between human papillomavirus (HPV) infection and cancer risk, and the importance of vaccination for all. To help spread this important message, we spoke with Prof. Daniel Kelly from Cardiff University, UK, who holds the Royal College of Nursing Chair of Nursing Research and is the co-Chair of the European Cancer Associations HPV Action Network. During the interview, we explored the relationship between HPV infection and various types of cancer, the scientific evidence supporting HPV vaccination, and addressed some of the challenges associated with vaccine hesitancy.
- [Impact of T2D on efficacy of immune checkpoint inhibitors in patients with cancer: Alessio Cortellini](https://touchoncology.com/immunotherapy/conference-hub/impact-of-t2d-on-efficacy-of-immune-checkpoint-inhibitors-in-patients-with-cancer-alessio-cortellini/): Type 2 diabetes mellitus (T2D) and obesity are both linked with an increased risk of developing cancer, in this study researchers at Imperial College London investigated whether diabetes had an impact on patient outcomes when treated with immune checkpoint inhibitors. touchONCOLOGY were delighted to speak with Dr Alessio Cortellini (Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy) around the aims, design and findings from his study investigating this link.
- [Angela DeMichele, ASCO 2023: The PALLAS trial, palbociclib with adjuvant endocrine therapy in patients with stage II-III breast cancer](https://touchoncology.com/breast-cancer/conference-hub/angela-demichele-asco-2023-the-pallas-trial-palbociclib-with-adjuvant-endocrine-therapy-in-patients-with-stage-ii-iii-breast-cancer/): The PALLAS trial assessed the efficacy of adding palbociclib to adjuvant endocrine therapy in patients with stage II-III breast cancer. In this touchONCOLOGY interview, we speak with Dr Angela DeMichele (Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA) to discuss the PALLAS trial and how it compares to the other CDK4/6 inhibitor adjuvant trials, including monarchE and NATALEE.
- [Binod Dhakal, ASCO 2023: The CARTITUDE-4 trial, ciltacabtagene autoleucel for patients with lenalidomide-refractory multiple myeloma](https://touchoncology.com/multiple-myeloma/conference-hub/binod-dhakal-asco-2023-the-cartitude-4-trial-ciltacabtagene-autoleucel-for-patients-with-lenalidomide-refractory-multiple-myeloma/): Lenalidomide is a standard of care in multiple myeloma. But with the prevalence of the lenalidomide-refractory population increasing, the CARTITUDE-4 trial aimed to assess ciltacabtagene autoleucel for this patient population. In this touchONCOLOGY interview, we speak with Dr Binod Dhakal (Medical College of Wisconsin, Milwaukee, WI, USA) to discuss the mechanism of action of ciltacabtagene autoleucel, the CARTITUDE-4 trial and the clinical significance of the findings.
- [Binod Dhakal, ASCO 2023: The treatment paradigm for multiple myeloma](https://touchoncology.com/multiple-myeloma/conference-hub/binod-dhakal-asco-2023-the-treatment-paradigm-for-multiple-myeloma/): The treatment paradigm for patients with multiple myeloma is very complex. In this touchONCOLOGY interview, we speak with Dr Binod Dhakal (Medical College of Wisconsin, Milwaukee, WI, USA) to break down the treatment paradigm in multiple myeloma, discussing how to handle different patient cases.
- [ZUMA-23 study of axicabtagene ciloleucel as first-line therapy in large B-cell lymphoma: Jason Westin, EHA 2023](https://touchoncology.com/hematology/conference-hub/zuma-23-study-of-axicabtagene-ciloleucel-as-first-line-therapy-in-large-b-cell-lymphoma-jason-westin-eha-2023/): ZUMA-23 (NCT05605899) is an on-going phase 3 study investigating axicabtagene ciloleucel (axi-cel) CAR T cell therapy as a first-line therapy in patients with high-risk large B-cell lymphoma. touchONCOLOGY caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss what previous clinical trials have taught us about axi-cel, what questions remain unanswered, and the aims, rationale and methodology of the ZUMA-23 study. He also touched upon topics to explore for 2023 in the field of haematology.
- [Axicabtagene ciloleucel for the treatment of large B-cell lymphoma: Jason Westin, EHA 2023](https://touchoncology.com/hematology/conference-hub/axicabtagene-ciloleucel-for-the-treatment-of-large-b-cell-lymphoma-jason-westin-eha-2023/): Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved to treat patients with relapsed/refractory large B-cell lymphoma. We caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss the current treatment paradigm for large B-cell lymphoma, the limitations of current therapeutic options and the mechanism of action of axi-cel.
- [Thierry André, ASCO 2023: The SOLISTICE phase III study, trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer](https://touchoncology.com/colorectal-cancer/conference-hub/thierry-andre-asco-2023-the-solistice-phase-iii-study-trifluridine-tipiracilbevacizumab-in-patients-with-unresectable-metastatic-colorectal-cancer/): The SOLISTICE phase III study aimed to assess trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer. In this touchONCOLOGY interview, we speak with Dr Thierry André (Hôpital Saint-Antoine, Paris, France) to discuss the rationale for the use of trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer, the secondary endpoint of overall survival and the key safety data.
- [Robin Foà, EHA 2023: José Carreras Award presentation – research on Philadelphia-positive acute lymphoblastic leukaemia](https://touchoncology.com/hematologic-malignancies/conference-hub/robin-foa-eha-2023-jose-carreras-award-presentation-research-on-philadelphia-positive-acute-lymphoblastic-leukaemia/): The presentation entitled ‘José Carreras Award: Ph+ ALL, from the worst malignancy to a chemo/transplant-free management?’ (Presentation #p200-3) was presented at the EHA 2023 Congress, 8–11 and 14–15 June 2023.
- [Robin Foà, EHA 2023: New developments in the treatment of Philadelphia-positive acute lymphoblastic leukaemia](https://touchoncology.com/hematologic-malignancies/conference-hub/robin-foa-eha-2023-new-developments-in-the-treatment-of-philadelphia-positive-acute-lymphoblastic-leukaemia/): The management of patients with Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL) has evolved over the last few decades, with new and exciting treatments becoming increasingly available. We caught up with Prof Robin Foà (Sapienza University, Rome, Italy) to discuss the history of Ph+ ALL research and top trials in the treatment of Ph+ ALL.
- [Arnon Kater, EHA 2023: MURANO substudy analysis: Venetoclax-rituximab in patients with chronic lymphocytic leukaemia](https://touchoncology.com/hematologic-malignancies/conference-hub/arnon-kater-eha-2023-murano-substudy-analysis-venetoclax-rituximab-in-patients-with-chronic-lymphocytic-leukaemia/): The phase III MURANO trial (NCT02005471) reported that venetoclax plus rituximab (venR) resulted in higher progression-free survival and overall survival than bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukaemia. The unmet needs in the treatment of chronic lymphocytic leukaemia, as well as the aims, main findings and clinical significance of the final MURANO substudy analysis, are discussed in this touchONCOLOGY interview with Prof Arnon Kater (Amsterdam UMC, University of Amsterdam; HOVON CLL working group, Amsterdam, the Netherlands).
- [Johan de Munter: Reflections as President of EONS, hopes for 2024 and European Cancer Nursing Day 2023](https://touchoncology.com/supportive-cancer-care/conference-hub/johan-de-munter-reflections-as-president-of-eons-hopes-for-2024-and-european-cancer-nursing-day-2023/): President of the European Oncology Nursing Society (EONS), Johan de Munter, reflects on his tenure as President, steering the society through the COVID-19 pandemic, his hopes for the society over the next 12 months, including a snapshot into what we can look forward to at the EONS16 annual meeting. Finally, he discusses the these of European Cancer Nursing Day 2023, and some of the key messages from this year.
- [Elias Jabbour, ASCO 2023: PhALLCON: A phase 3 study comparing ponatinib vs imatinib patients with Ph+ALL](https://touchoncology.com/hematologic-malignancies/conference-hub/elias-jabbour-asco-2023-phallcon-a-phase-3-study-comparing-ponatinib-vs-imatinib-patients-with-phall/): Filmed as a highlight of ASCO 2023
- [Michael K Gibson, ASCO 2023: Highlights in upper GI oncology](https://touchoncology.com/gastrointestinal-cancers/conference-hub/michael-k-gibson-asco-2023-highlights-in-upper-gi-oncology/): touchONCOLOGY spoke with editorial board member Michael K Gibson (Vanderbilt University, Nashville, TN, USA) to discuss his highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2–6, June 2023 in the field of upper GI oncology, including the phase 3 ATTRACTION-5 study and a randomized, phase II study assessing toripalimab for the treatment of treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma.
- [Ben Weinberg, ASCO 2023: Highlights from the PROSPECT, AtezoTRIBE, D-ToRCH and DESTINY-CRC02 trials](https://touchoncology.com/colorectal-cancer/conference-hub/ben-weinberg-asco-2023-highlights-from-the-prospect-atezotribe-d-torch-and-destiny-crc02-trials/): touchONCOLOGY spoke with editorial board member Ben Weinberg (Georgetown University, Washington, DC, USA) to discuss his highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2–6, June 2023. This includes data from the Plenary Session randomized phase 3 noninferiority PROSPECT trial, showing that neoadjuvant FOLFOX with selective use of 5-FU chemoradiotherapy (5-FU CRT) was noninferior to 5-FU CRT in participants with locally advanced rectal cancer. He also highlights the translational analysis of the AtezoTRIBE study, the breakthrough D-ToRCH study and the primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.
- [Sara Tolaney, ASCO 2023: Highlights from the NATALEE trial of ribociclib and endocrine therapy in the treatment of breast cancer](https://touchoncology.com/breast-cancer/conference-hub/sara-tolaney-asco-2023-highlights-from-the-natalee-trial-of-ribociclib-and-endocrine-therapy-in-the-treatment-of-breast-cancer/): touchONCOLOGY spoke with editorial board member Sara Tolaney (Dana-Farber Cancer Institute, Boston, MA, USA) to discuss her highlights from the ASCO annual meeting. She highlights data from the NATALEE study (NCT03701334), which met its primary endpoint at interim analysis, thus showing clinically meaningful benefit for patients with early breast cancer.
- [Sara Tolaney, ASCO 2023: Primary outcome analysis of the phase 3 SONIA trial and the final overall survival results from the phase 3 TROPiCS-02 study](https://touchoncology.com/breast-cancer/conference-hub/sara-tolaney-asco-2023-primary-outcome-analysis-of-the-phase-3-sonia-trial-and-the-final-overall-survival-results-from-the-phase-3-tropics-02-study/): touchONCOLOGY spoke with editorial board member Sara Tolaney (Dana-Farber Cancer Institute, Boston, MA, USA) to discuss her highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2–6, June 2023. These include the phase 3 SONIA trial (NCT03425838) assessing CDK4/6 inhibitors for patients with HR+, HER2- advanced breast cancer, and the final overall survival results from the phase 3 TROPiCS-02 study (NCT03901339) of sacituzumab govitecan in patients with HR+/HER2– metastatic breast cancer.
- [Rimas Lukas, ASCO 2023: The INDIGO phase III trial, vorasidenib in patients with IDH1/2 mutated grade 2 glioma](https://touchoncology.com/neuro-oncology/conference-hub/rimas-lukas-asco-2023-the-indigo-phase-iii-trial-vorasidenib-in-patients-with-idh1-2-mutated-grade-2-glioma/): The INDIGO phase III trial assessed the use of vorasidenib in patients with IDH1/2 mutated grade 2 glioma. In this touchONCOLOGY interview, we speak with Dr Rimas Lukas (Malnati Brain Tumor Institute, Northwestern University, Chicago, IL, USA) to discuss the mechanism of action in vorasidenib, the outcomes of the INDIGO trial, and what these findings mean for the field of low grade glioma.
- [Ken Kato, ASCO 2023: Highlights in upper gastrointestinal cancers](https://touchoncology.com/gastrointestinal-cancers/conference-hub/ken-kato-asco-2023-highlights-in-upper-gastrointestinal-cancers/): touchONCOLOGY are joined by editorial board member Dr Ken Kato (National Cancer Centre Hospital, Tokyo, Japan) to discuss a few of his highlights from the 2023 American Society of Clinical Oncology (ASCO) annual meeting.
- [Pamela Kearns: Exciting steps forward through collaborative clinical trials in paediatric oncology](https://touchoncology.com/pediatric-oncology/conference-hub/pamela-kearns-exciting-steps-forward-through-collaborative-clinical-trials-in-paediatric-oncology/): Professor Pamela Kearns (Director, Cancer Research UK Clinical Trials Unit, UK) discusses some of the most important clinical trials she is currently involved with in the field of paediatric oncology. She includes:
- [Pamela Kearns: Highlights from SIOP Europe 2023](https://touchoncology.com/pediatric-oncology/conference-hub/pamela-kearns-highlights-from-siop-europe-2023/): Professor Pamela Kearns (University of Birmingham, UK) joins touchONCOLOGY to discuss her highlights from the first face-to-face annual meeting of the European Society of Paediatric Oncology (SIOPE Europe) since the COVID-19 pandemic (Valencia, 8-12 May 2023). She celebrates joint sessions with patient advocacy groups, and the importance of patient and parent experience in the debate about the impact of artificial intelligence on paediatric oncology and new initiatives around patient reported outcome measures and how we gather patient information.

## Specialities
- [Bladder Cancer](https://touchoncology.com/speciality/bladder-cancer/)
- [Breast Cancer](https://touchoncology.com/speciality/breast-cancer/)
- [Colorectal Cancer](https://touchoncology.com/speciality/colorectal-cancer/)
- [COVID-19](https://touchoncology.com/speciality/covid-19/)
- [Dermatologic Cancers](https://touchoncology.com/speciality/dermatologic-cancers/)
- [Diagnostics and Screening](https://touchoncology.com/speciality/diagnostics-and-screening/)
- [Gastrointestinal Cancers](https://touchoncology.com/speciality/gastrointestinal-cancers/)
- [Genitourinary Cancer](https://touchoncology.com/speciality/genitourinary-cancers/)
- [Gynecologic Cancers](https://touchoncology.com/speciality/gynecologic-cancers/)
- [Hematology](https://touchoncology.com/speciality/hematology/)
- [Hematologic Malignancies](https://touchoncology.com/speciality/hematologic-malignancies/)
- [Head and Neck Cancer](https://touchoncology.com/speciality/head-and-neck-cancer/)
- [Immunotherapy](https://touchoncology.com/speciality/immunotherapy/)
- [Leukemia](https://touchoncology.com/speciality/leukemia/)
- [Lymphoma](https://touchoncology.com/speciality/lymphoma/)
- [Multiple Myeloma](https://touchoncology.com/speciality/multiple-myeloma/)
- [Ovarian Cancer](https://touchoncology.com/speciality/ovarian-cancer/)
- [Pancreatic Cancer](https://touchoncology.com/speciality/pancreatic-cancer/)
- [Lung Cancer](https://touchoncology.com/speciality/lung-cancer/)
- [Prostate Cancer](https://touchoncology.com/speciality/prostate-cancer/)
- [Renal Cancer](https://touchoncology.com/speciality/renal-cancer/)
- [Endocrine Cancers](https://touchoncology.com/speciality/endocrine-cancers/)
- [Pediatric Oncology](https://touchoncology.com/speciality/pediatric-oncology/)
- [Policy](https://touchoncology.com/speciality/policy/)
- [Sarcoma](https://touchoncology.com/speciality/sarcoma/)
- [Supportive Cancer Care](https://touchoncology.com/speciality/supportive-cancer-care/)
- [Soft Tissue Tumors](https://touchoncology.com/speciality/soft-tissue-tumors/)
- [Neuro-oncology](https://touchoncology.com/speciality/neuro-oncology/)
- [Pathology](https://touchoncology.com/speciality/pathology/)
- [Radiology](https://touchoncology.com/speciality/radiology/)
- [Radiotherapy](https://touchoncology.com/speciality/radiotherapy/)
- [Rare Diseases](https://touchoncology.com/speciality/rare-diseases/)

## Journals
- [EUROPEAN ONCOLOGY & HAEMATOLOGY](https://touchoncology.com/journals/european-oncology-haematology/): Comprising articles contributed by renowned thought leaders, European Oncology & Haematology is a peer reviewed, free-to-access, bi-annual journal that aims to disseminate best practice through review articles addressing the most important and salient developments in the Oncological & Haematology field in practical terms. 

European Oncology & Haematology
Frequency: Two print issues per year (Summer & Winter); ePub ahead of print throughout the year.
Print ISSN: 2045-5275 Electronic ISSN: 2045-5283
Indexing: EMBASE, Google Scholar, Genamics JournalSeek
- [touchREVIEWS in Oncology & Haematology](https://touchoncology.com/journals/touchreviews-in-oncology-haematology/)